BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497. [PMID: 11170959 DOI: 10.1086/318501] [Cited by in Crossref: 688] [Cited by in F6Publishing: 646] [Article Influence: 32.8] [Reference Citation Analysis]
Number Citing Articles
1 Andersson K, Chung RT. Hepatitis C Virus in the HIV-infected patient. Clin Liver Dis 2006;10:303-20, viii. [PMID: 16971263 DOI: 10.1016/j.cld.2006.05.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
2 Matsukura M, Chu FF, Au M, Lu H, Chen J, Rietkerk S, Barrios R, Farley JD, Montaner JS, Montessori VC, Walker DC, Côté HC. Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy. AIDS 2008;22:1226-9. [DOI: 10.1097/qad.0b013e328303be16] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Conti S, Masocco M, Pezzotti P, Toccaceli V, Vichi M, Crialesi R, Frova L, Rezza G. Excess Mortality From Liver Disease and Other Non–AIDS-Related Diseases Among HIV-Infected Individuals in Italy: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2002;29:105-7. [DOI: 10.1097/00126334-200201010-00017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
4 Hung C, Chang S. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections. Journal of Antimicrobial Chemotherapy 2004;54:849-53. [DOI: 10.1093/jac/dkh438] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
5 Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin SR, Sasadeusz J, Matthews G, Dore GJ, Shaw T, Sozzi V, Yuen L, Lau G, Ayres A, Thio C, Avihingsanon A, Ruxrungtham K, Locarnini S, Revill PA. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology 2008;48:741-9. [PMID: 18571815 DOI: 10.1002/hep.22386] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
6 Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006;13:683-9. [PMID: 16970600 DOI: 10.1111/j.1365-2893.2006.00749.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 69] [Article Influence: 5.5] [Reference Citation Analysis]
7 Núñez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis 2003;37:1678-85. [PMID: 14689351 DOI: 10.1086/379774] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
8 Pérez-olmeda M, Soriano V, Asensi V, Morales D, Romero M, Ochoa A, Sánchez-montero F, Santin M, Guardiola J, Blanch J, Núñez M, Jiménez-nácher I, García-samaniego J, The Hcv/hiv Spanish Study Group. Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α -2b Plus Ribavirin. AIDS Research and Human Retroviruses 2003;19:1083-9. [DOI: 10.1089/088922203771881176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
9 Cengiz C, Park JS, Saraf N, Dieterich DT. HIV and Liver Diseases: Recent Clinical Advances. Clinics in Liver Disease 2005;9:647-66. [DOI: 10.1016/j.cld.2005.07.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Brunet L, Moodie EE, Rollet K, Cooper C, Walmsley S, Potter M, Klein MB; Canadian Co-infection Cohort Investigators. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis 2013;57:663-70. [PMID: 23811492 DOI: 10.1093/cid/cit378] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
11 Miró JM, Torre-Cisnero J, Moreno A, Tuset M, Quereda C, Laguno M, Vidal E, Rivero A, Gonzalez J, Lumbreras C, Iribarren JA, Fortún J, Rimola A, Rafecas A, Barril G, Crespo M, Colom J, Vilardell J, Salvador JA, Polo R, Garrido G, Chamorro L, Miranda B. [GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. Enferm Infecc Microbiol Clin 2005;23:353-62. [PMID: 15970168 DOI: 10.1157/13076175] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
12 Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004;19:357-65. [PMID: 15061745 DOI: 10.1111/j.1525-1497.2004.30613.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 3.5] [Reference Citation Analysis]
13 Osinusi A, Chary A, Winters MA, Naggie S, Masur H, Polis MA, Kottilil S, Holodniy M. IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. J Med Virol 2012;84:1522-7. [PMID: 22930497 DOI: 10.1002/jmv.23376] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Braitstein P, Palepu A, Dieterich D, Benhamou Y, Montaner JS. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C: . AIDS 2004;18:2221-34. [DOI: 10.1097/00002030-200411190-00002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
15 Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, Sherman M, Sulkowski MS, Dieterich DT, Rigsby MO, Wright TL, Hernandez MD, Jain MK, Khatri GK, Sterling RK, Bonacini M, Martyn CA, Aytaman A, Llovet JM, Brown ST, Bini EJ. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study. Journal of Hepatology 2007;47:527-37. [DOI: 10.1016/j.jhep.2007.06.010] [Cited by in Crossref: 167] [Cited by in F6Publishing: 148] [Article Influence: 11.1] [Reference Citation Analysis]
16 Farrell G, Comiskey C. Dualities of Living With HIV/HCV Co-Infection: Patients' Perspectives From Those who are Ineligible for or Nonresponsive to Treatment. Journal of the Association of Nurses in AIDS Care 2014;25:9-22. [DOI: 10.1016/j.jana.2012.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, Rivas P, Barreiro P, Mura MS, Babudieri S, Garcia-Samaniego J, González-Lahoz J, Soriano V. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177-82. [PMID: 16688096 DOI: 10.1097/01.qai.0000221683.44940.62] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 7.5] [Reference Citation Analysis]
18 Tenorio AR, Landay AL. HIV: so near and yet so far. Curr HIV/AIDS Rep 2013;10:1-2. [PMID: 23266604 DOI: 10.1007/s11904-012-0151-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Tien PC, Kovacs A, Bacchetti P, French AL, Augenbraun M, Cole SR, Hessol N, Justman J; Women's Interagency HIV Study. Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study. Clin Infect Dis 2004;39:1363-70. [PMID: 15494914 DOI: 10.1086/424879] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
20 Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, Rela M, Heaton N, O'Grady JG. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl. 2004;10:1271-1278. [PMID: 15376307 DOI: 10.1002/lt.20233] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 4.1] [Reference Citation Analysis]
21 Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002;36:S201-9. [PMID: 12407595 DOI: 10.1053/jhep.2002.36380] [Cited by in Crossref: 17] [Cited by in F6Publishing: 45] [Article Influence: 0.9] [Reference Citation Analysis]
22 Thomson EC, Main J. Epidemiology of hepatitis C virus infection in HIV-infected individuals. J Viral Hepat 2008;15:773-81. [PMID: 18435718 DOI: 10.1111/j.1365-2893.2008.00981.x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutierrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy. AIDS Res Hum Retroviruses 2016;32:6-11. [PMID: 26414169 DOI: 10.1089/AID.2014.0299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab. 2012;13:1327-1344. [PMID: 22746301 DOI: 10.2174/138920012803341302] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
25 Wagner G, Chan Osilla K, Garnett J, Ghosh-Dastidar B, Bhatti L, Goetz MB, Witt M. Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS Res Treat 2011;2011:903480. [PMID: 22110904 DOI: 10.1155/2011/903480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
26 Irvin R, McAdams-Mahmoud A, Hickman D, Wilson J, Fenwick W, Chen I, Irvin N, Falade-Nwulia O, Sulkowski M, Chaisson R, Thomas DL, Mehta SH. Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening. J Community Med Health Educ 2016;6:431. [PMID: 27525192 DOI: 10.4172/2161-0711.1000431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
27 Shire NJ, Sherman KE. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future. Clin Infect Dis 2005;41 Suppl 1:S63-8. [PMID: 16265616 DOI: 10.1086/429498] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
28 Barcaui HS, Tavares GC, May SB, Brandão-Mello CE, Amendola Pires MM, Barroso PF. Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil. PLoS One 2013;8:e67734. [PMID: 23874441 DOI: 10.1371/journal.pone.0067734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
29 Kress KD. Antiretroviral-associated hepatotoxicity. Curr Infect Dis Rep 2005;7:103-7. [DOI: 10.1007/s11908-005-0068-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Sabin CA. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era: . AIDS 2002;16:S61-8. [DOI: 10.1097/00002030-200216004-00009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
31 Trullas JC, Cofan F, Cocchi S, Cervera C, Linares L, Aguero F, Oppenheimer F, Moreno A, Campistol JM, Miró JM. Short Communication: Effect of Thymoglobulin Induction on HIV-Infected Renal Transplant Recipients: Differences between HIV-Positive and HIV-Negative Patients. AIDS Research and Human Retroviruses 2007;23:1161-5. [DOI: 10.1089/aid.2007.0015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
32 Gonzalez SA, Zhang C, Fiel MI, Chung S, Zhang L, Jacobson IM, Talal AH. Hepatic inflammatory cytokine mRNA expression in hepatitis C virus–human immunodeficiency virus co-infection. J Viral Hepat 2008;15:331-8. [DOI: 10.1111/j.1365-2893.2007.00949.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
33 Sulkowski MS, Thomas DL. Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. AIDS 2005;19 Suppl 3:S8-12. [PMID: 16251833 DOI: 10.1097/01.aids.0000192064.09281.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
34 Falusi OM, Pulvirenti J, Sarazine J, Shastri P, Gail C, Glowacki R. HIV-infected inpatients in the HAART era: how do hepatitis C virus coinfected patients differ? AIDS Patient Care STDS 2003;17:13-6. [PMID: 12614516 DOI: 10.1089/108729103321042872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
35 Liu L, Nardo D, Li E, Wang GP. CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3. AIDS 2016;30:691-700. [PMID: 26645605 DOI: 10.1097/QAD.0000000000000997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Obienu O, Nwokediuko S. Selected biochemical and hematological abnormalities in Nigerians with human immunodeficiency virus and hepatitis C virus coinfection. Hepat Med 2011;3:63-8. [PMID: 24367222 DOI: 10.2147/HMER.S21735] [Reference Citation Analysis]
37 Berenguer J, Alejos B, Hernando V, Viciana P, Salavert M, Santos I, Gómez-sirvent JL, Vidal F, Portilla J, Del Amo J. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS 2012;26:2241-6. [DOI: 10.1097/qad.0b013e3283574e94] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
38 Pereira SA, Caixas U, Branco T, Germano I, Lampreia F, Papoila AL, Monteiro EC. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br J Clin Pharmacol 2008;66:551-5. [PMID: 18662298 DOI: 10.1111/j.1365-2125.2008.03238.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
39 Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007;45:439-44. [PMID: 17468669 DOI: 10.1097/QAI.0b013e318061b5d9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
40 Clausen LN, Lundbo LF, Benfield T. Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol 2014; 20(34): 12132-12143 [PMID: 25232248 DOI: 10.3748/wjg.v20.i34.12132] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
41 Sánchez-Quijano A, Leal M, Lissen E. [Chronic hepatitis C in patients coinfected by human immunodeficiency virus]. Gastroenterol Hepatol 2002;25:423-31. [PMID: 12069706 DOI: 10.1016/s0210-5705(02)70277-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Matthews GV, Dore GJ. HIV and hepatitis C coinfection. Journal of Gastroenterology and Hepatology 2008;23:1000-8. [DOI: 10.1111/j.1440-1746.2008.05489.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
43 Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis. JAIDS Journal of Acquired Immune Deficiency Syndromes 2008;49:358-68. [DOI: 10.1097/qai.0b013e31818c7efe] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
44 Righi E, Beltrame A, Bassetti M, Lindstrom V, Mazzarello G, Dentone C, Di Biagio A, Ratto S, Viscoli C. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection. 2008;36:358-361. [PMID: 18642111 DOI: 10.1007/s15010-008-7319-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
45 Dray-spira R, Lert F. Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy: . AIDS 2003;17:283-90. [DOI: 10.1097/00002030-200302140-00001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
46 Morales AL, Liriano-Ward L, Tierney A, Sang M, Lalos A, Hassan M, Nair V, Schiano T, Satoskar R, Smith C. Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. Clin Transplant 2017;31. [PMID: 28239909 DOI: 10.1111/ctr.12941] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
47 Vachon M, Perumalswami P, Dieterich DT. Hepatobiliary Manifestations of Human Immunodeficiency Virus. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 1060-82. [DOI: 10.1002/9781119950509.ch41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Halfon P. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02. Journal of Hepatology 2008;48:765-73. [DOI: 10.1016/j.jhep.2008.01.025] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
49 Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB; Canadian Co-infection Cohort Study Investigators. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010;24:1857-65. [PMID: 20479633 DOI: 10.1097/QAD.0b013e32833adbb5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
50 Wilde JT. HIV and HCV coinfection in haemophilia. Haemophilia 2004;10:1-8. [DOI: 10.1046/j.1351-8216.2003.00828.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
51 Pontali E, Ferrari F. Prevalence of Hepatitis B virus and/or Hepatitis C virus co-infections in prisoners infected with the Human Immunodeficiency Virus. Int J Prison Health 2008;4:77-82. [PMID: 18464061 DOI: 10.1080/17449200802038207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
52 Mazzocato S, Orsetti E, Gesuita R, Piraccini F, Drenaggi D, Barchiesi F. Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry. Scand J Infect Dis 2014;46:797-802. [PMID: 25244675 DOI: 10.3109/00365548.2014.952245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Dhillon R, Rossi S, Herrine SK. Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients. Ther Clin Risk Manag 2008;4:789-96. [PMID: 19209261 DOI: 10.2147/tcrm.s2093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
54 Fang CT, Chen PJ, Chen MY, Hung CC, Chang SC, Chang AL, Chen DS. Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. J Hepatol 2003;39:1028-35. [PMID: 14642622 DOI: 10.1016/s0168-8278(03)00416-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
55 Ulveling D, Le Clerc S, Cobat A, Labib T, Noirel J, Laville V, Coulonges C, Carpentier W, Nalpas B, Heim MH, Poynard T, Cerny A, Pol S, Bochud PY, Dabis F, Theodorou I, Lévy Y, Salmon D, Abel L, Dominguez S, Zagury JF; HEPAVIH ANRS CO13 Cohort Study Group., Swiss Hepatitis C Cohort Study Group., French ANRS HC EP 26 Genoscan Study Group. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2016;64:1462-72. [PMID: 27339598 DOI: 10.1002/hep.28695] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
56 Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H; GESIDA HIV/HCV cohort. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009;63:1256-63. [PMID: 19363085 DOI: 10.1093/jac/dkp106] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
57 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. [PMID: 17393513 DOI: 10.1002/hep.21627] [Cited by in Crossref: 407] [Cited by in F6Publishing: 371] [Article Influence: 27.1] [Reference Citation Analysis]
58 de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, Marcos A, Demetris A, Jain A, Fung JJ. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6:2983-2993. [PMID: 17062005 DOI: 10.1111/j.1600-6143.2006.01546.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
59 Fuster D, Tsui JI, Cheng DM, Quinn EK, Bridden C, Nunes D, Libman H, Saitz R, Samet JH. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. Alcohol Clin Exp Res. 2013;37:1527-1535. [PMID: 23647488 DOI: 10.1111/acer.12129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
60 Conigliaro J, Madenwald T, Bryant K, Braithwaite S, Gordon A, Fultz SL, Maisto S, Samet J, Kraemer K, Cook R, Day N, Roach D, Richey S, Justice A. The Veterans Aging Cohort Study: observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus-infected veterans. Alcohol Clin Exp Res 2004;28:313-21. [PMID: 15112939 DOI: 10.1097/01.alc.0000113414.73220.21] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
61 Chen M, Wong WW, Law MG, Kiertiburanakul S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim BL, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Chen YM. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. PLoS One 2016;11:e0150512. [PMID: 26933963 DOI: 10.1371/journal.pone.0150512] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
62 Adeyemi OM. Hepatitis C in HIV-positive Patients—Treatment and Liver Disease Outcomes. Journal of Clinical Gastroenterology 2007;41:75-87. [DOI: 10.1097/01.mcg.0000225592.16448.f3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
63 Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, Smith J, McClure MO, Karayiannis P. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60:837-845. [PMID: 21139063 DOI: 10.1136/gut.2010.217166] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 10.0] [Reference Citation Analysis]
64 Kohli A, Funk E, Burbelo P, Barrett L, Meissner EG, Santich B, Shaffer A, Johl J, Sidharthan S, Moir S, Kottilil S, Fauci AS. Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse. J Med Virol 2015;87:544-52. [PMID: 25611329 DOI: 10.1002/jmv.24089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
65 Giri S, Nieber K, Bader A. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages. Expert Opinion on Drug Metabolism & Toxicology 2010;6:895-917. [DOI: 10.1517/17425251003792521] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
66 Klein MB, Lee T, Brouillette M, Sheehan NL, Walmsley S, Wong DK, Conway B, Hull M, Cooper C, Haidar S, Vezina S, Annable L, Young S, Zubyk W, Singer J; for the CTN194 (PICCO) Investigators. Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial. HIV Clinical Trials 2014;15:161-75. [DOI: 10.1310/hct1504-161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
67 Viale P, Baccarani U, Tavio M. Liver transplant in patients with HIV: infection risk associated with HIV and post-transplant immunosuppression. Curr Infect Dis Rep 2008;10:74-81. [PMID: 18377819 DOI: 10.1007/s11908-008-0013-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
68 Carlos Martín J, Castilla J, López M, Arranz R, González-Lahoz J, Soriano V. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 2004;5:125-31. [PMID: 15248136 DOI: 10.1310/YFV8-FE5K-5LN9-DQ4C] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
69 Mendes-correa MC, Widman A, Brussi MLP, Guastini CF, Gianini RJ. Incidence and Predictors of Severe Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C in Brazil. AIDS Patient Care and STDs 2008;22:701-7. [DOI: 10.1089/apc.2007.0216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
70 Tsai JC, Hung CC, Chang SY, Liu WC, Wu CH, Su YC, Wu PY, Luo YZ, Chang LH, Sun HY, Chang SC. Increasing incidence of recent hepatitis C virus infection among persons seeking voluntary counselling and testing for HIV and sexually transmitted infections in Taiwan. BMJ Open 2015;5:e008406. [PMID: 26463221 DOI: 10.1136/bmjopen-2015-008406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
71 Berenguer J, Bellon JM, Miralles P, Alvarez E, Castillo I, Cosin J, Lopez JC, Sanchez Conde M, Padilla B, Resino S. Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in Patients with HIV and Hepatitis C Virus Coinfection. Clinical Infectious Diseases 2008;46:137-43. [DOI: 10.1086/524080] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
72 Resino S, Bellón JM, Asensio C, Micheloud D, Miralles P, Vargas A, Catalán P, López JC, Alvarez E, Cosin J. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis. 2010;10:244. [PMID: 20723207 DOI: 10.1186/1471-2334-10-244] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
73 Chary A, Holodniy M. Interferon combination therapy for HIV/hepatitis C virus coinfection. Immunotherapy 2011;3:1087-102. [PMID: 21913831 DOI: 10.2217/imt.11.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Shaw E, Castellote J, Santín M, Xiol X, Euba G, Gudiol C, Lopez C, Ariza X, Gudiol F. Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a case-control study. Eur J Clin Microbiol Infect Dis 2006;25:291-8. [DOI: 10.1007/s10096-006-0136-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
75 Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, Dore GJ, Tyndall MW. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011;18:32-41. [PMID: 20196806 DOI: 10.1111/j.1365-2893.2010.01279.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
76 Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, Koziel MJ, Sherman KE; and the Multicenter Hemophilia Cohort Study Group. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 2005;105:533-41. [DOI: 10.1182/blood-2004-04-1452] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
77 Soriano V, Martin-Carbonero L, Vispo E, Labarga P, Barreiro P. [Human immunodeficiency virus infection and viral hepatitis]. Enferm Infecc Microbiol Clin. 2011;29:691-701. [PMID: 21978797 DOI: 10.1016/j.eimc.2011.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
78 Bick JA. HIV and Viral Hepatitis in Corrections: A Public Health Opportunity. In: Greifinger RB, editor. Public Health Behind Bars. New York: Springer; 2007. pp. 103-26. [DOI: 10.1007/978-0-387-71695-4_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
79 Bourlière M, Charles Duclos-vallée J, Pol S. Foie et antirétroviraux : hépatotoxicité, stéatose et monitoring en cas d’hépatopathie. Gastroentérologie Clinique et Biologique 2007;31:895-905. [DOI: 10.1016/s0399-8320(07)73987-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
80 Moltó J, Llibre JM, Ribera E, Mínguez C, del Río JS, Pedrol E, Vallecillo G, Cedeño S, Valle M, Miranda C, Negredo E, Clotet B; SQV-HEP Study Group. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. J Antimicrob Chemother 2009;63:992-7. [PMID: 19279052 DOI: 10.1093/jac/dkp070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
81 Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, Goodman Z, Parker R, Lifson A, Capozza T. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464-473. [PMID: 19225402 DOI: 10.1097/qai.0b013e318198a88a] [Cited by in Crossref: 128] [Cited by in F6Publishing: 62] [Article Influence: 9.8] [Reference Citation Analysis]
82 Bhattacharya D, Umbleja T, Carrat F, Chung RT, Peters MG, Torriani F, Andersen J, Currier JS. Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 2010;55:170-5. [PMID: 20622678 DOI: 10.1097/QAI.0b013e3181e36420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
83 Cooper CL, DeForest J, Gill J, Lalonde R; Canadian HIV Trials Network (CTN) Co-Infection Core Group. Barriers preventing liver transplantation in Canadians with HIV-infection--perceptions of HIV specialists. Can J Gastroenterol 2007;21:179-82. [PMID: 17377647 DOI: 10.1155/2007/769752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
84 Hershow RC, O'Driscoll PT, Handelsman E, Pitt J, Hillyer G, Serchuck L, Lu M, Chen KT, Yawetz S, Pacheco S, Davenny K, Adeniyi-Jones S, Thomas DL. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 2005;40:859-67. [PMID: 15736020 DOI: 10.1086/428121] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
85 Saiz de la Hoya-Zamácola P, Marco-Mouriño A, Clemente-Ricote G, Portilla-Sogorb J, Boix-Martínez V, Núñez-Martínez O, Reus-Bañuls S, Teixidó i Pérez N. [Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. Enferm Infecc Microbiol Clin 2006;24:568-75. [PMID: 17125677 DOI: 10.1157/13093878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
86 Zhang RF, Sun HQ, Huang Q, Wang JR, Zhang XX, Liu XN, Ma Q, Lu HZ. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia. Haemophilia 2010;16:502-7. [PMID: 20028427 DOI: 10.1111/j.1365-2516.2009.02170.x] [Reference Citation Analysis]
87 Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, Weintrob A, Ganesan A, Maguire J, Klopfer S, Brandt C. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis. 2011;203:1815-1823. [PMID: 21606540 DOI: 10.1093/infdis/jir180] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
88 Thomson EC, Smith JA, Klenerman P. The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J Gen Virol. 2011;92:2227-2236. [PMID: 21775583 DOI: 10.1099/vir.0.033910-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
89 Macparland SA, Vali B, Ostrowski MA. Immunopathogenesis of HIV/hepatitis C virus coinfection. Future Virology 2011;6:1115-28. [DOI: 10.2217/fvl.11.80] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Moreno A, Moreno A, Pérez-Elías MJ, Quereda C, Fernández-Muñoz R, Antela A, Moreno L, Bárcena R, López-San Román A, Celma ML, García-Martos M, Moreno S. Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature. Hum Pathol 2006;37:1344-9. [PMID: 16949926 DOI: 10.1016/j.humpath.2006.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
91 Khalsa JH, Kresina T, Sherman K, Vocci F. Medical management of HIV-hepatitis C virus coinfection in injection drug users. Clin Infect Dis 2005;41 Suppl 1:S1-6. [PMID: 16265605 DOI: 10.1086/429488] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
92 Park JS, Saraf N, Dieterich DT. HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep 2006;8:67-74. [DOI: 10.1007/s11894-006-0066-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
93 Re VL, Kostman JR, Gross R, Reddy KR, Mounzer K, Zemel BS, Rennert H, Stieritz DD, Putt M, Frank I, Strom BL. Incidence and Risk Factors for Weight Loss During Dual HIV/Hepatitis C Virus Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;44:344-50. [DOI: 10.1097/qai.0b013e31802f12d3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
94 Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN, Lundgren JD. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS. 2005;19:2117-2125. [PMID: 16284461 DOI: 10.1097/01.aids.0000194799.43799.ea] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 5.3] [Reference Citation Analysis]
95 Sogni P, Salmon-céron D, Podevin P. Prise en charge des complications de la cirrhose chez les patients VIH co-infectés par une hépatite virale B ou C. La Presse Médicale 2005;34:1579-83. [DOI: 10.1016/s0755-4982(05)84228-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
96 Saiz de la Hoya-zamácola P, Marco-mouriño A, Clemente-ricote G, Portilla-sogorb J, Boix-martínez V, Núñez-martínez Ó, Reus-bañuls S, Teixidó i Pérez N. Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Gastroenterología y Hepatología 2006;29:551-9. [DOI: 10.1157/13094351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
97 Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459. [PMID: 15282352 DOI: 10.1056/nejmoa032653] [Cited by in Crossref: 675] [Cited by in F6Publishing: 195] [Article Influence: 37.5] [Reference Citation Analysis]
98 Lai AR, Tashima KT, Taylor LE. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus. AIDS Patient Care STDS 2006;20:678-92. [PMID: 17052138 DOI: 10.1089/apc.2006.20.678] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
99 Johnston B, Conly J. Solid organ transplantation and HIV: A changing paradigm. Can J Infect Dis Med Microbiol 2008;19:425-9. [PMID: 19436573 DOI: 10.1155/2008/479752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
100 Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, Bhagani S, Emery VC, Dusheiko GM, Klenerman P. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 2008;197:1558-1566. [PMID: 18419344 DOI: 10.1086/587843] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 5.4] [Reference Citation Analysis]
101 Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Journal of Antimicrobial Chemotherapy 2010;65:1079-85. [DOI: 10.1093/jac/dkq086] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
102 Vallet-Pichard A, Pol S. Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment. J Hepatol 2004;41:156-66. [PMID: 15246224 DOI: 10.1016/j.jhep.2004.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
103 Alcalde R, Nishiya A, Casseb J, Inocêncio L, Fonseca LA, Duarte AJ. Prevalence and distribution of the GBV-C/HGV among HIV-1-infected patients under anti-retroviral therapy. Virus Res 2010;151:148-52. [PMID: 20420864 DOI: 10.1016/j.virusres.2010.04.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
104 Myers T, Allman D, Xu K, Remis RS, Aguinaldo J, Burchell A, Calzavara L, Swantee C. The prevalence and correlates of hepatitis C virus (HCV) infection and HCV–HIV co-infection in a community sample of gay and bisexual men. International Journal of Infectious Diseases 2009;13:730-9. [DOI: 10.1016/j.ijid.2008.11.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
105 Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E. HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. Front Pharmacol 2017;8:90. [PMID: 28289388 DOI: 10.3389/fphar.2017.00090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
106 Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, Falco V, Quer J, Ocaña I, Ruiz I, Buti M, Pahissa A, Esteban R, Guardia J. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007;14:228-38. [DOI: 10.1111/j.1365-2893.2006.00779.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
107 Chan DP, Sun H, Wong HT, Lee S, Hung C. Sexually acquired hepatitis C virus infection: a review. International Journal of Infectious Diseases 2016;49:47-58. [DOI: 10.1016/j.ijid.2016.05.030] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 12.3] [Reference Citation Analysis]
108 Torno MS, Witt MD, Sue DY. Hepatopulmonary Syndrome in HIV--Hepatitis C Virus Coinfection: A Case Report and Review of the Literature. Clinical Infectious Diseases 2004;39:e25-9. [DOI: 10.1086/422455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
109 Kadam JS, Talal AH. Changing treatment paradigms: hepatitis C virus in HIV-infected patients. AIDS Patient Care STDS 2007;21:154-68. [PMID: 17428183 DOI: 10.1089/apc.2006.0126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
110 Sayegh SE, Keller MJ, Huprikar S, Murphy B. Solid organ transplantation in HIV-infected recipients. Pediatric Transplantation 2004;8:214-21. [DOI: 10.1111/j.1399-3046.2004.00190.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
111 Lombardi R, Sambatakou H, Mariolis I, Cokkinos D, Papatheodoridis GV, Tsochatzis EA. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver Dis. 2016;48:1471-1477. [PMID: 27623186 DOI: 10.1016/j.dld.2016.08.117] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
112 Christie T, Jiwani B, Asrat G, Montessori V, Mathias R, Montaner J. Ethical and scientific issues surrounding solid organ transplantation in HIV-positive patients: Absence of evidence is not evidence of absence. Can J Infect Dis Med Microbiol 2006;17:15-8. [PMID: 18418478 DOI: 10.1155/2006/286301] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
113 Keating SM, Dodge JL, Norris PJ, Heitman J, Gange SJ, French AL, Glesby MJ, Edlin BR, Latham PS, Villacres MC, Greenblatt RM, Peters MG; Women’s Interagency HIV Study. The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study. PLoS One 2017;12:e0181004. [PMID: 28902848 DOI: 10.1371/journal.pone.0181004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
114 Hashempour T, Moayedi J, Mousavi Z, Esmaeli M, Asadzadeh A, Hasanshahi Z, Dehghani B. Incidence of Hepatotoxicity in Iranian Patients With HIV on Antiretroviral Therapies and Its Correlation with Virologic Response to HIV Treatment. Lab Med 2021;52:369-74. [PMID: 33345285 DOI: 10.1093/labmed/lmaa106] [Reference Citation Analysis]
115 Martín-Carbonero L, Soriano V, Valencia E, García-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-71. [PMID: 11709090 DOI: 10.1089/08892220152644160] [Cited by in Crossref: 149] [Cited by in F6Publishing: 140] [Article Influence: 7.5] [Reference Citation Analysis]
116 Baillargeon J, Snyder N, Soloway RD, Paar D, Baillargeon G, Spaulding AC, Pollock BH, Arcari CM, Williams BA, Raimer BG. Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep 2009;124:120-6. [PMID: 19413034 DOI: 10.1177/003335490912400115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
117 Weitzman G, Jacobson I. Peginterferon α-2b in the treatment of hepatitis C. Future Virology 2006;1:279-92. [DOI: 10.2217/17460794.1.3.279] [Reference Citation Analysis]
118 Bruno R, Sacchi P, Puoti M, Soriano V, Filice G. HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 2002;97:1598-606. [PMID: 12135007 DOI: 10.1111/j.1572-0241.2002.05817.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
119 Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, Iser D, Slavin J, Buranapraditkun S, Marks P, Matthews G. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol. 2009;83:7649-7658. [PMID: 19458009 DOI: 10.1128/jvi.00183-09] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
120 Katsarou O, Touloumi G, Antoniou A, Kouramba A, Hatzakis A, Karafoulidou A. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients. Haemophilia 2005;11:360-5. [PMID: 16011588 DOI: 10.1111/j.1365-2516.2005.01109.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
121 Guaraldi G, Cocchi S, Motta A, Ciaffi S, Codeluppi M, Bonora S, Di Benedetto F, Masetti M, Floridia M, Baroncelli S, Pinetti D, Bertolini A, Gerunda GE, Esposito R. Efficacy and safety of atazanavir in patients with end-stage liver disease. Infection 2009;37:250-5. [PMID: 19471855 DOI: 10.1007/s15010-008-8025-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
122 Molt?? J, Valle M, Blanco A, Negredo E, Delavarga M, Miranda C, Miranda J, Domingo P, Vilar?? J, Tural C, Costa J, Barbanoj MJ, Clotet B. Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment: Influence of Liver Fibrosis. Clinical Pharmacokinetics 2007;46:85-92. [DOI: 10.2165/00003088-200746010-00005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
123 Chamie G, Bonacini M, Bangsberg DR, Stapleton JT, Hall C, Overton ET, Scherzer R, Tien PC. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis. 2007;44:577-583. [PMID: 17243063 DOI: 10.1086/511038] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
124 Weiss JJ, Osorio G, Ryan E, Marcus SM, Fishbein DA. Prevalence and patient awareness of medical comorbidities in an urban AIDS clinic. AIDS Patient Care STDS 2010;24:39-48. [PMID: 20095901 DOI: 10.1089/apc.2009.0152] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
125 Mchutchison JG. Hepatitis C advances in antiviral therapy: What is accepted treatment now? J Gastroenterol Hepatol 2002;17:431-41. [DOI: 10.1046/j.1440-1746.2002.02777.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
126 Falconer K, Gonzalez VD, Reichard O, Sandberg JK, Alaeus A. Spontaneous HCV clearance in HCV/HIV-1 coinfection associated with normalized CD4 counts, low level of chronic immune activation and high level of T cell function. Journal of Clinical Virology 2008;41:160-3. [DOI: 10.1016/j.jcv.2007.11.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
127 Rosenthal E, Salmon-céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, May T, François M, Burty C, Jougla E, Costagliola D, Morlat P, Chêne G, Cacoub P; the Mortavic/Mortalité 2005 Study Group. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Medicine 2009;10:282-9. [DOI: 10.1111/j.1468-1293.2008.00686.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 6.1] [Reference Citation Analysis]
128 Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. World J Gastroenterol 2009; 15(8): 996-1003 [PMID: 19248201 DOI: 10.3748/wjg.15.996] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
129 Puri P, Saraswat VA, Dhiman RK, Anand AC, Acharya SK, Singh SP, Chawla YK, Amarapurkar DN, Kumar A, Arora A, Dixit VK, Koshy A, Sood A, Duseja A, Kapoor D, Madan K, Srivastava A, Kumar A, Wadhawan M, Goel A, Verma A, Shalimar, Pandey G, Malik R, Agrawal S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol 2016;6:119-45. [PMID: 27493460 DOI: 10.1016/j.jceh.2016.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
130 Soriano V, Barreiro P, Nuñez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006;57:815-8. [PMID: 16556638 DOI: 10.1093/jac/dkl068] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 3.2] [Reference Citation Analysis]
131 Terilli RR, Cox AL. Immunity and hepatitis C: a review. Curr HIV/AIDS Rep. 2013;10:51-58. [PMID: 23180007 DOI: 10.1007/s11904-012-0146-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
132 Zhang X, Xu J, Peng H, Ma Y, Han L, Ruan Y, Su B, Wang N, Shao Y. HCV coinfection associated with slower disease progression in HIV-infected former plasma donors naïve to ART. PLoS One 2008;3:e3992. [PMID: 19098990 DOI: 10.1371/journal.pone.0003992] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
133 Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-1713. [PMID: 14643119 DOI: 10.1016/s0140-6736(03)14844-1] [Cited by in Crossref: 370] [Cited by in F6Publishing: 102] [Article Influence: 20.6] [Reference Citation Analysis]
134 Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int. 2013;33 Suppl 1:68-79. [PMID: 23286849 DOI: 10.1111/liv.12063] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
135 Sherman KE, Soriano V, Chung RT. Human immunodeficiency virus and liver disease: conference proceedings. Hepatology 2010;51:1046-54. [PMID: 20041404 DOI: 10.1002/hep.23394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
136 Wiktor S, Ford N, Ball A, Hirnschall G. HIV and HCV: distinct infections with important overlapping challenges. J Int AIDS Soc 2014;17:19323. [PMID: 25079438 DOI: 10.7448/IAS.17.1.19323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Escolano Hortelano CM, Ramos Rincón JM, Gutiérrez Rodero F, Masiá Canuto M, Hernández Aguado I, Benito Santaleocadia C, Padilla Urrea S, Martín-Hidalgo A. [Changes in the spectrum of morbidity and mortality in hospital admissions of HIV infected patients during the HAART era]. Med Clin (Barc) 2004;122:1-5. [PMID: 14733866 DOI: 10.1016/s0025-7753(04)74124-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
138 Lu T, Chang H, Chen L, Chu M, Ou N, Jen I. Changes in Causes of Death and Associated Conditions Among Persons with HIV/AIDS After the Introduction of Highly Active Antiretroviral Therapy in Taiwan. Journal of the Formosan Medical Association 2006;105:604-9. [DOI: 10.1016/s0929-6646(09)60158-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Kim YC, Ahn JY, Kim JM, Kim YJ, Park DW, Yoon YK, Song JY, Kim SW, Lee JS, Choi BY, Choi YS, Choi JY, Han MG, Kang C, Choi JY. Human Immunodeficiency Virus (HIV) and Hepatitis Virus Coinfection among HIV-Infected Korean Patients: The Korea HIV/AIDS Cohort Study. Infect Chemother 2017;49:268-74. [PMID: 29299894 DOI: 10.3947/ic.2017.49.4.268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
140 González Alonso R, Bárcena R, Blesa C, Garcia M, Moreno A, Fortun J, Martin P, Quereda C, de Vicente E. Liver transplantation in a patient coinfected with human immunodeficiency virus and hepatitis C virus. Transplantation Proceedings 2003;35:1846-7. [DOI: 10.1016/s0041-1345(03)00635-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
141 Akimov S, Adeyemi OM. Peginterferon-α 2a in the treatment of chronic hepatitis C. Future Virology 2006;1:689-701. [DOI: 10.2217/17460794.1.6.689] [Reference Citation Analysis]
142 Sánchez-conde M, Pérez-latorre L, Rincón D, Miralles P, Catalina M, López JC, Bañares R, Berenguer J. Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis. JAIDS Journal of Acquired Immune Deficiency Syndromes 2015;69:e142-4. [DOI: 10.1097/qai.0000000000000639] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
143 Iddi S, Minja CA, Silago V, Benjamin A, Mpesha J, Henerico S, Kidenya BR, Mshana SE, Mirambo MM. High Human Immunodeficiency Virus (HIV) Viral Load and Coinfection with Viral Hepatitis Are Associated with Liver Enzyme Abnormalities among HIV Seropositive Patients on Antiretroviral Therapy in the Lake Victoria Zone, Tanzania. AIDS Res Treat 2019;2019:6375714. [PMID: 31275646 DOI: 10.1155/2019/6375714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
144 Bini EJ, Currie SL, Shen H, Bräu N, Schmidt W, Anand BS, Cheung R, Wright TL; VA HCV-001 Study Group. National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infection. J Clin Gastroenterol 2006;40:732-9. [PMID: 16940888 DOI: 10.1097/00004836-200609000-00014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
145 Rajbhandari R, Jun T, Khalili H, Chung RT, Ananthakrishnan AN. HBV/HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV. J Viral Hepat. 2016;23:820-829. [PMID: 27291562 DOI: 10.1111/jvh.12555] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
146 Koike K, Tsukada K, Yotsuyanagi H, Moriya K, Kikuchi Y, Oka S, Kimura S. Prevalence of coinfection with human immunodeficiency virus and hepatitis C virus in Japan. Hepatol Res 2007;37:2-5. [PMID: 17300692 DOI: 10.1111/j.1872-034X.2007.00011.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
147 Kim A, Dorn A, Bouajram R, Saab S. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. HIV Med 2007;8:312-21. [DOI: 10.1111/j.1468-1293.2007.00476.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
148 Lei AH, Yang Q, Cai WP, Liu YF, Lan Y, Qin AP, Hu FY, Zhou J. Clinical Significance of Myeloid-Derived Suppressor Cells in Human Immunodeficiency Virus-1/ Hepatitis C Virus-coinfected Patients. Scand J Immunol 2016;83:438-44. [DOI: 10.1111/sji.12429] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
149 Merriman NA, Porter SB, Brensinger CM, Reddy KR, Chang K. Racial Difference in Mortality Among U.S. Veterans with HCV/HIV Coinfection. Am J Gastroenterol 2006;101:760-7. [DOI: 10.1111/j.1572-0241.2006.00531.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
150 Núñez M. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. Journal of Hepatology 2006;44:S132-9. [DOI: 10.1016/j.jhep.2005.11.027] [Cited by in Crossref: 152] [Cited by in F6Publishing: 144] [Article Influence: 9.5] [Reference Citation Analysis]
151 Pearlman BL. Hepatitis C treatment update. The American Journal of Medicine 2004;117:344-52. [DOI: 10.1016/j.amjmed.2004.03.024] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 3.2] [Reference Citation Analysis]
152 Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr 2004;37:1367-75. [PMID: 15483466 DOI: 10.1097/01.qai.0000131932.21612.49] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
153 Zhou K, Terrault N. Management of hepatitis B in special populations. Best Pract Res Clin Gastroenterol. 2017;31:311-320. [PMID: 28774413 DOI: 10.1016/j.bpg.2017.06.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
154 Lanternier F, Roulot D, Bentata M, Pol S, Viard J, Gordien E, Jeantils V, Ziol M, Lortholary O. Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV at the HAART era: the role of mixed steatosis. Gastroentérologie Clinique et Biologique 2007;31:822-7. [DOI: 10.1016/s0399-8320(07)73972-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
155 Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 2005;41:1186-95. [PMID: 16163639 DOI: 10.1086/444501] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
156 Murcia J, Portilla J, Bedia M, Palazón JM, Sánchez-Payá J, Saiz de la Hoya P, Payá A, Boix V, Merino E, Reus S. [Chronic hepatitis C virus infection and associated liver disease among the inmates of a Spanish prison]. Enferm Infecc Microbiol Clin 2009;27:206-12. [PMID: 19246126 DOI: 10.1016/j.eimc.2008.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
157 Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, Gueit I, Mortier E, Costagliola D, Morlat P. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. HIV Med. 2015;16:230-239. [PMID: 25522874 DOI: 10.1111/hiv.12204] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
158 Braitstein P, Justice A, Bangsberg DR, Yip B, Alfonso V, Schechter MT, Hogg RS, Montaner JS. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006;20:323-31. [PMID: 16439865 DOI: 10.1097/01.aids.0000198091.70325.f4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
159 Webster DP, Klenerman P, Collier J, Jeffery KJ. Development of novel treatments for hepatitis C. Lancet Infect Dis. 2009;9:108-117. [PMID: 19179226 DOI: 10.1016/s1473-3099(09)70020-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
160 Nelson M, Matthews G, Brook M, Main J; on behalf of the British HIV Association. BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus. HIV Med 2003;4:52-62. [DOI: 10.1046/j.1468-1293.4.s1.2.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
161 Moreno S, González J, Lekander I, Martí B, Oyagüez I, Sánchez-de la Rosa R, Casado MA. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. Clin Ther 2010;32:2232-45. [PMID: 21316539 DOI: 10.1016/S0149-2918(10)80026-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Potter M, Klein MB. Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. HIV Therapy 2009;3:189-207. [DOI: 10.2217/17584310.3.2.189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Stapleton J. A New Variable Influencing HCV–Related Liver Disease in HIV–HCV Coinfected Individuals? Gastroenterology 2007;133:2042-5. [DOI: 10.1053/j.gastro.2007.10.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
164 Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat. 2007;14:176-182. [PMID: 17305883 DOI: 10.1111/j.1365-2893.2006.00797.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
165 Fleming C, Tumilty S, Murray J, Nunes D. Challenges in the Treatment of Patients Coinfected with HIV and Hepatitis C Virus: Need for Team Care. CLIN INFECT DIS 2005;40:S349-54. [DOI: 10.1086/427452] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
166 Konerman MA, Mehta SH, Sutcliffe CG, Vu T, Higgins Y, Torbenson MS, Moore RD, Thomas DL, Sulkowski MS. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014;59:767-75. [PMID: 24436062 DOI: 10.1002/hep.26741] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.9] [Reference Citation Analysis]
167 Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat. 2007;14:239-248. [PMID: 17381715 DOI: 10.1111/j.1365-2893.2006.00824.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
168 Mendes-corrêa MCJ, Barone AA. Hepatitis C in patients co-infected with human immunodeficiency virus. A review and experience of a Brazilian ambulatory. Rev Inst Med trop S Paulo 2005;47:59-64. [DOI: 10.1590/s0036-46652005000200001] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
169 Stosor V. Organ Transplantation in HIV Patients: Current Status and New Directions. Curr Infect Dis Rep 2013;15:526-35. [PMID: 24142801 DOI: 10.1007/s11908-013-0381-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
170 Ahr B, Robert-Hebmann V, Devaux C, Biard-Piechaczyk M. Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 2004;1:12. [PMID: 15214962 DOI: 10.1186/1742-4690-1-12] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 3.3] [Reference Citation Analysis]
171 Ormaasen V, Sandvik L, Dudman SG, Bruun JN. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis. 2007;39:51-57. [PMID: 17366013 DOI: 10.1080/00365540600904779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
172 Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49:1605-1615. [PMID: 19842982 DOI: 10.1086/644771] [Cited by in Crossref: 155] [Cited by in F6Publishing: 153] [Article Influence: 12.9] [Reference Citation Analysis]
173 Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS. 2005;19:356-365. [PMID: 15989431 DOI: 10.1089/apc.2005.19.356] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
174 Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-569. [PMID: 11462196 DOI: 10.1086/321909] [Cited by in Crossref: 656] [Cited by in F6Publishing: 614] [Article Influence: 31.2] [Reference Citation Analysis]
175 Fischer MJ, Wyatt CM, Gordon K, Gibert CL, Brown ST, Rimland D, Rodriguez-Barradas MC, Justice AC, Parikh CR; VACS Project Team. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010;53:222-6. [PMID: 20104121 DOI: 10.1097/QAI.0b013e3181b980d4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
176 Hansen NB, Cavanaugh CE, Vaughan EL, Connell CM, Tate DC, Sikkema KJ. The influence of personality disorder indication, social support, and grief on alcohol and cocaine use among HIV-positive adults coping with AIDS-related bereavement. AIDS Behav 2009;13:375-84. [PMID: 17846878 DOI: 10.1007/s10461-007-9308-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
177 Sánchez-Conde M, Berenguer J, Miralles P, Alvarez F, Carlos Lopez J, Cosin J, Pilar C, Ramirez M, Gutierrez I, Alvarez E. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase. Clin Infect Dis. 2006;43:640-644. [PMID: 16886160 DOI: 10.1086/506440] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
178 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
179 Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol 2018;31:35-41. [PMID: 29333065 DOI: 10.20524/aog.2017.0204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
180 Alqahtani SA, Aljumah AA, Hashim A, Alenazi TH, AlJawad M, Al Hamoudi WK, Alghamdi MY. Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation. Ann Saudi Med. 2020;40:273-280. [PMID: 32564624 DOI: 10.5144/0256-4947.2020.273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
181 Xiao P, Usami O, Suzuki Y, Ling H, Shimizu N, Hoshino H, Zhuang M, Ashino Y, Gu H, Hattori T. Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4. AIDS 2008;22:1749-57. [PMID: 18753859 DOI: 10.1097/QAD.0b013e328308937c] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
182 Chen CH, Chung CY, Wang LH, Lin C, Lin HL, Lin HC. Risk of cancer among HIV-infected patients from a population-based nested case-control study: implications for cancer prevention. BMC Cancer 2015;15:133. [PMID: 25885746 DOI: 10.1186/s12885-015-1099-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
183 Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav 2010;14:1213-26. [PMID: 20232242 DOI: 10.1007/s10461-010-9684-1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 7.8] [Reference Citation Analysis]
184 Hopkins S, Lambourne J, Farrell G, Mccullagh L, Hennessy M, Clarke S, Mulcahy F, Bergin C. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals*. HIV Med 2006;7:248-54. [DOI: 10.1111/j.1468-1293.2006.00365.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
185 Stein MD, Herman DS, Kim HN, Howell A, Lambert A, Madden S, Moitra E, Blevins CE, Anderson BJ, Taylor LE, Pinkston MM. A Randomized Trial Comparing Brief Advice and Motivational Interviewing for Persons with HIV-HCV Co-infection Who Drink Alcohol. AIDS Behav 2021;25:1013-25. [PMID: 33047258 DOI: 10.1007/s10461-020-03062-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, van der Ende ME. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197:292-4. [PMID: 18177248 DOI: 10.1086/524690] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
187 Cacoub P, Sène D, Rosenthal E, Pol S. [HIV and hepatitis C virus coinfection]. Gastroenterol Clin Biol 2008;32:S82-9. [PMID: 18675185 DOI: 10.1016/S0399-8320(08)73270-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
188 El-Serag HB, Giordano TP, Kramer J, Richardson P, Souchek J. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol 2005;3:175-83. [PMID: 15704052 DOI: 10.1016/s1542-3565(04)00620-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
189 Castaneda-Sceppa C, Bermudez OI, Wanke C, Forrester JE. Predictors of insulin resistance among Hispanic adults infected with or at risk of infection with the human immunodeficiency virus and hepatitis C virus. J Viral Hepat 2008;15:878-87. [PMID: 19087226 DOI: 10.1111/j.1365-2893.2008.01021.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
190 Bova C, Ogawa LF, Sullivan-Bolyai S. Hepatitis C treatment experiences and decision making among patients living with HIV infection. J Assoc Nurses AIDS Care 2010;21:63-74. [PMID: 19853480 DOI: 10.1016/j.jana.2009.07.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
191 Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, Matchaba G, Sangweni P, Metcalf J, Pool N, Orsega S, Emery S. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 2011;25:1727-35. [DOI: 10.1097/qad.0b013e328349bbf3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
192 Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat. 2005;12:223-235. [PMID: 15850462 DOI: 10.1111/j.1365-2893.2005.00600.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
193 Krain A, Wisnivesky JP, Garland E, Mcginn T. Prevalence of Human Immunodeficiency Virus Testing in Patients With Hepatitis B and C Infection. Mayo Clinic Proceedings 2004;79:51-6. [DOI: 10.4065/79.1.51] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
194 Mohite AR, Gambhire PA, Pawar SV, Jain SS, Contractor QQ, Rathi PM. Changing clinical profile and factors associated with liver enzyme abnormalities among HIV-infected persons. Trop Doct 2017;47:205-11. [PMID: 27342920 DOI: 10.1177/0049475516655068] [Reference Citation Analysis]
195 García-samaniego J, Soriano V, Miró J, Romero J, Bruguera M, Castilla J, Esteban J, Gonz´lez J, Lissen E, Moreno A, Moreno S, Moreno-otero R, Ortega E, Quereda C, Rodríguez M, Sánchez-tapias J; The Spanish Hepatitis-HIV Consensus Panel. Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. HIV Clinical Trials 2015;3:99-114. [DOI: 10.1310/h2cf-3kna-q3y9-c3g1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
196 Thio CL. Chronic hepatitis B or C in HIV-infected persons: pathogenesis and management. J Gastroenterol Hepatol 2004;19:S138-44. [DOI: 10.1111/j.1440-1746.2004.03665.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
197 Verma S, Wang C, Govindarajan S, Kanel G, Squires K, Bonacini M. Do Type and Duration of Antiretroviral Therapy Attenuate Liver Fibrosis in HIV--Hepatitis C Virus--Coinfected Patients? Clinical Infectious Diseases 2006;42:262-70. [DOI: 10.1086/499055] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
198 England K, Thorne C, Newell M. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. The Lancet Infectious Diseases 2006;6:83-90. [DOI: 10.1016/s1473-3099(06)70381-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
199 Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18:1169-1177. [PMID: 15166532 DOI: 10.1097/00002030-200405210-00010] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 5.7] [Reference Citation Analysis]
200 Chang JJ, Wightman F, Bartholomeusz A, Ayres A, Kent SJ, Sasadeusz J, Lewin SR. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol. 2005;79:3038-3051. [PMID: 15709024 DOI: 10.1128/jvi.79.5.3038-3051.2005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
201 Pathania S, Kaur N, Kumar S, Sashindran VK, Puri P. A cross-sectional study of liver function tests in HIV-infected persons in Western India. Med J Armed Forces India 2017;73:23-8. [PMID: 28123241 DOI: 10.1016/j.mjafi.2016.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
202 Bräu N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, Frost KR, Kostman JR. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology. 2004;39:989-998. [PMID: 15057903 DOI: 10.1002/hep.20107] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.2] [Reference Citation Analysis]
203 Ray SC, Thomas DL. Hepatitis C. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2157-85. [DOI: 10.1016/b978-0-443-06839-3.00154-5] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
204 Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 2010;8:1002-12. [PMID: 20851211 DOI: 10.1016/j.cgh.2010.08.024] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 9.4] [Reference Citation Analysis]
205 Jones R, Dunning J, Nelson M. HIV and hepatitis C co-infection: HIV and HEPATITIS C CO-INFECTION. International Journal of Clinical Practice 2005;59:1082-7. [DOI: 10.1111/j.1742-1241.2005.00596.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
206 Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. The Lancet Infectious Diseases 2004;4:437-44. [DOI: 10.1016/s1473-3099(04)01059-x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
207 Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171. [PMID: 15057920 DOI: 10.1002/hep.20119] [Cited by in Crossref: 1226] [Cited by in F6Publishing: 1119] [Article Influence: 68.1] [Reference Citation Analysis]
208 Jang JY, Chung RT. Chronic hepatitis C. Gut Liver. 2011;5:117-132. [PMID: 21814590 DOI: 10.5009/gnl.2011.5.2.117] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
209 Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, Wood KC, Holmberg SD; HIV Outpatient Study (HOPS) Investigators. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;36:363-7. [PMID: 12539079 DOI: 10.1086/345953] [Cited by in Crossref: 126] [Cited by in F6Publishing: 120] [Article Influence: 6.6] [Reference Citation Analysis]
210 Anadol E, Lust K, Boesecke C, Schwarze-Zander C, Mohr R, Wasmuth JC, Rockstroh JK, Trebicka J. Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients. PLoS One 2018;13:e0191118. [PMID: 29346443 DOI: 10.1371/journal.pone.0191118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
211 Salmon-ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. Journal of Hepatology 2005;42:799-805. [DOI: 10.1016/j.jhep.2005.01.022] [Cited by in Crossref: 230] [Cited by in F6Publishing: 198] [Article Influence: 13.5] [Reference Citation Analysis]
212 . Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006;20:741-9. [DOI: 10.1097/01.aids.0000216375.99560.a2] [Cited by in Crossref: 156] [Cited by in F6Publishing: 150] [Article Influence: 9.8] [Reference Citation Analysis]
213 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2007;3:469-76. [PMID: 24395487 DOI: 10.1007/s11908-007-1004-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
214 Nijmeijer BM, Sarrami-Forooshani R, Steba GS, Schreurs RR, Koekkoek SM, Molenkamp R, Schinkel J, Reiss P, Siegenbeek van Heukelom ML, van der Valk M, Ribeiro CM, Geijtenbeek TB. HIV-1 exposure and immune activation enhance sexual transmission of Hepatitis C virus by primary Langerhans cells. J Int AIDS Soc 2019;22:e25268. [PMID: 30932366 DOI: 10.1002/jia2.25268] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
215 Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G. Factors that influence an HIV coinfected patient’s decision to start hepatitis C treatment. AIDS Patient Care STDS. 2009;23:993-999. [PMID: 19929229 DOI: 10.1089/apc.2009.0153] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
216 Sugawara Y, Tamura S, Kokudo N. Liver transplantation in HCV/HIV positive patients. World J Gastrointest Surg 2011; 3(2): 21-28 [PMID: 21394322 DOI: 10.4240/wjgs.v3.i2.21] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
217 Ferri RS, Kirton CA. Hepatitis C Virus/HIV Coinfection: A New Challenge for Nurses in AIDS Care. Journal of the Association of Nurses in AIDS care 2003;14:7S-17S. [DOI: 10.1177/1055329003254332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
218 Zare Marzouni H, Davachi B, Rezazadeh M, Salehi Milani M, Matinfard S. Diagnostic Value of Hepatic Vein Ultrasound in Early Detection of Liver Cirrhosis. Galen Med J 2018;7:e1140. [PMID: 34466440 DOI: 10.22086/gmj.v0i0.1140] [Reference Citation Analysis]
219 Shire NJ, Sherman KE. Vaccination against hepatitis a and b in patients with hiv. Curr hepatitis rep 2006;5:63-7. [DOI: 10.1007/s11901-006-0006-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
220 Price JC, Seaberg EC, Latanich R, Budoff MJ, Kingsley LA, Palella FJ Jr, Witt MD, Post WS, Thio CL. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol 2014;109:695-704. [PMID: 24642579 DOI: 10.1038/ajg.2014.32] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 8.8] [Reference Citation Analysis]
221 Waters L, John L, Nelson M. Non-nucleoside reverse transcriptase inhibitors: a review: NNRTIs: a review. International Journal of Clinical Practice 2007;61:105-18. [DOI: 10.1111/j.1742-1241.2006.01146.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
222 Strader DB. Coinfection with HIV and Hepatitis C Virus in Injection Drug Users and Minority Populations. Clinical Infectious Diseases 2005;41:S7-S13. [DOI: 10.1086/429489] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
223 Morales D, Skoulakis EC, Acevedo SF. 14-3-3s are potential biomarkers for HIV-related neurodegeneration. J Neurovirol 2012;18:341-53. [PMID: 22811265 DOI: 10.1007/s13365-012-0121-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
224 Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis. 2012;55:728-736. [PMID: 22610932 DOI: 10.1093/cid/cis500] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 11.8] [Reference Citation Analysis]
225 Mendes-correa MC, Widman A, Brussi MLP, Guastini CF, Cavalheiro NDP, Melo CE, Barone AA, Gianini RJ. Clinical and histological characteristics of HIV and hepatitis C virus-co-infected patients in Brazil: a case series study. Rev Inst Med trop S Paulo 2008;50:213-7. [DOI: 10.1590/s0036-46652008000400005] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
226 Katsounas A, Schlaak JF, Lempicki RA. CCL5: a double-edged sword in host defense against the hepatitis C virus. Int Rev Immunol 2011;30:366-78. [PMID: 22053974 DOI: 10.3109/08830185.2011.593105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
227 Shevitz AH, Knox TA. Nutrition in the era of highly active antiretroviral therapy. Clin Infect Dis 2001;32:1769-75. [PMID: 11360219 DOI: 10.1086/320761] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
228 Daugherty T, Bonacini M. Therapy of hepatitis C in patients with HIV infection. Expert Rev Anti Infect Ther 2005;3:375-84. [PMID: 15954854 DOI: 10.1586/14787210.3.3.375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
229 Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003;75:425-9. [PMID: 12605104 DOI: 10.1097/01.TP.0000046943.35335.18] [Cited by in Crossref: 99] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
230 Ahsan MH, Gill AF, Lackner AA, Veazey RS. Acute and chronic T cell dynamics in the livers of simian immunodeficiency virus-infected macaques. J Virol 2012;86:5244-52. [PMID: 22379078 DOI: 10.1128/JVI.07080-11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
231 Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, Aderaye G, Schuppe-Koistinen I, Lindquist L, Aklillu E. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients. PLoS One 2014;9:e94271. [PMID: 24714066 DOI: 10.1371/journal.pone.0094271] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
232 Al-mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;44:463-9. [DOI: 10.1097/qai.0b013e318030ff8e] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
233 Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003;36:1030-8. [PMID: 12684916 DOI: 10.1086/368186] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 3.5] [Reference Citation Analysis]
234 Fregni G, Maresca AF, Jalbert V, Caignard A, Scott-Algara D, Cramer EB, Rouveix E, Béné MC, Capron C. High number of CD56(bright) NK-cells and persistently low CD4+ T-cells in a hemophiliac HIV/HCV co-infected patient without opportunistic infections. Virol J 2013;10:33. [PMID: 23351719 DOI: 10.1186/1743-422X-10-33] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
235 Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, Chaisson RE, Moore RD, Sulkowski MS. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005;41:123-31. [DOI: 10.1002/hep.20541] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
236 Negri F, Missale G, Antoni AD, Porta C. Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Transl Oncol 2021;14:101153. [PMID: 34144349 DOI: 10.1016/j.tranon.2021.101153] [Reference Citation Analysis]
237 Ferreros I, Lumbreras B, Hurtado I, Pérez-Hoyos S, Hernández-Aguado I. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users. Addiction 2008;103:651-9. [PMID: 18339110 DOI: 10.1111/j.1360-0443.2008.02135.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
238 Kim J, Jung Y. Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate Cells. Vitam Horm. 2016;102:121-149. [PMID: 27450733 DOI: 10.1016/bs.vh.2016.04.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
239 Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, Michelet C, Pol S, Perronne C, Cacoub P. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat. 2007;14:183-188. [PMID: 17305884 DOI: 10.1111/j.1365-2893.2006.00791.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 6.7] [Reference Citation Analysis]
240 Olaechea PM, Alvarez-Lerma F, Sánchez M, Torres A, Palomar M, Fernández P, Miró JM, Cisneros JM, Torres M; Sociedad Española de Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias., Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. [Evaluation of the status of patients with severe infection, criteria for intensive care unit admittance. Spanish Society for Infectious Diseases and Clinical Microbiology. Spanish Society of Intensive and Critical Medicine and Coronary Units]. Enferm Infecc Microbiol Clin 2009;27:342-52. [PMID: 19409668 DOI: 10.1016/j.eimc.2008.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
241 González-Requena D, Núñez M, Jiménez-Nacher I, González-Lahoz J, Soriano V. Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. AIDS Res Hum Retroviruses 2004;20:698-700. [PMID: 15307912 DOI: 10.1089/0889222041524562] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
242 Weiss JJ, Morgello S. Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices. Gen Hosp Psychiatry 2009;31:531-7. [PMID: 19892211 DOI: 10.1016/j.genhosppsych.2009.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
243 Lutz P, Wasmuth JC, Nischalke HD, Vidovic N, Grünhage F, Lammert F, Oldenburg J, Rockstroh JK, Sauerbruch T, Spengler U. Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene. Eur J Med Res. 2011;16:335-341. [PMID: 21813376 DOI: 10.1186/2047-783x-16-8-335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
244 Lombardi R, Lever R, Smith C, Marshall N, Rodger A, Bhagani S, Tsochatzis E. Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. Ann Gastroenterol 2017;30:349-56. [PMID: 28469366 DOI: 10.20524/aog.2017.0141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
245 Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 2007;45:262-8. [PMID: 17414926 DOI: 10.1097/QAI.0b013e3180559219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
246 Larrousse M, Laguno M, Segarra M, De Lazzari E, Martinez E, Blanco JL, León A, Deulofeu R, Miquel R, Milinkovic A, Lonca M, Miró JM, Biglia A, Murillas J, Gatell JM, Mallolas J. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007;46:304-11. [PMID: 18172937 DOI: 10.1097/qai.0b013e3181520502] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
247 Pérez-olmeda M, Ríos P, Núñez M, García-samaniego J, Romero M, Soriano V. Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment: . AIDS 2002;16:493-5. [DOI: 10.1097/00002030-200202150-00026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
248 Kim AY, Chung RT. HIV and hepatitis C virus coinfection update. Curr hepatitis rep 2004;3:83-90. [DOI: 10.1007/s11901-004-0014-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Hashiani AA, Sadeghi F, Ayubi E, Rezaeian S, Moradi Y, Mansori K, Gholamaliei B, Mohammadbeigi A, Khazaei S. Prevalence of HIV, Hepatitis B and C Virus Co-infections among Iranian High-Risk Groups: A Systematic Review and Meta-Analysis. Malays J Med Sci 2019;26:37-48. [PMID: 31303849 DOI: 10.21315/mjms2019.26.3.3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Rodriguez B, Bobak DA. Management of Hepatitis C in HIV-infected Patients. Curr Infect Dis Rep. 2005;7:91-102. [PMID: 15727735 DOI: 10.1007/s11908-005-0067-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
251 Osborn M, Guest J, Rimland D. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease. HIV Med 2007;8:271-9. [DOI: 10.1111/j.1468-1293.2007.00469.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
252 Obermeier M, Ingiliz P, Weitner L, Cordes C, Moll A, Hintsche B, Schlote F, Koeppe S, Christensen S, Mayr C, Baumgarten A. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept. Eur J Med Res 2011;16:237-42. [PMID: 21719398 DOI: 10.1186/2047-783x-16-5-237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
253 Ahmed A, Keeffe EB. Update on chronic hepatitis C. Compr Ther 2003;29:224-32. [PMID: 14989044 DOI: 10.1007/s12019-003-0026-3] [Reference Citation Analysis]
254 Jain MK, Parekh NK, Hester J, Lee WM. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS. 2006;20:817-822. [PMID: 17192146 DOI: 10.1089/apc.2006.20.817] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
255 Satapathy SK, Lingisetty CS, Williams SE. Acute Kidney Dysfunction in Patients with Chronic Hepatitis C Virus Infection: Analysis of Viral and Non-viral Factors. J Clin Exp Hepatol 2014;4:8-13. [PMID: 25755529 DOI: 10.1016/j.jceh.2014.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
256 Sulkowski MS. Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. J Hepatol 2006;44:S49-55. [PMID: 16360232 DOI: 10.1016/j.jhep.2005.11.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
257 Ruiz-Sancho A, Soriano V. [HIV and HCV coinfection]. Enferm Infecc Microbiol Clin 2006;24:335-45; quiz 346. [PMID: 16762261 DOI: 10.1157/13089670] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
258 Karayiannis P. Current therapies for chronic hepatitis B virus infection. Expert Rev Anti Infect Ther. 2004;2:745-760. [PMID: 15482237 DOI: 10.1586/14789072.2.5.745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
259 Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M;  APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325. [PMID: 16729309 DOI: 10.1002/hep.21178] [Cited by in Crossref: 1954] [Cited by in F6Publishing: 1862] [Article Influence: 122.1] [Reference Citation Analysis]
260 Pena M, Horga J, Zapater P. Variations of pharmacokinetics of drugs in patients with cirrhosis. Expert Review of Clinical Pharmacology 2015;9:441-58. [DOI: 10.1586/17512433.2016.1135733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
261 Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J. Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;44:174-8. [DOI: 10.1097/qai.0b013e31802b812d] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
262 Cachay ER, Wyles DL, Goicoechea M, Torriani FJ, Ballard C, Colwell B, Gish RG, Mathews WC. Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. AIDS Res Ther 2011;8:29. [PMID: 21831314 DOI: 10.1186/1742-6405-8-29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
263 Chen C, Wen X, Yadav A, Belviso N, Kogut S, McCauley J. Outcomes in human immunodeficiency virus-infected recipients of heart transplants. Clin Transplant 2019;33:e13440. [PMID: 30387534 DOI: 10.1111/ctr.13440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
264 Ghosn J. Liver Fibrosis and Antiretroviral Therapy. Clinical Infectious Diseases 2006;42:271-2. [DOI: 10.1086/499060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Brandão AB, Mariante-Neto G. Liver transplantation in HIV-positive patients: the position of the Brazilian groups. Arq Gastroenterol 2005;42:161-6. [PMID: 16200252 DOI: 10.1590/s0004-28032005000300007] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
266 Osinusi A, Rasimas JJ, Bishop R, Proschan M, McLaughlin M, Murphy A, Cortez KJ, Polis MA, Masur H, Rosenstein D. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J Acquir Immune Defic Syndr. 2010;53:357-363. [PMID: 20101190 DOI: 10.1097/qai.0b013e3181c7a29d] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
267 Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ; ACTG 5071 Study Team. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 2006;20:345-51. [PMID: 16439867 DOI: 10.1097/01.aids.0000206500.16783.2e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
268 Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007;14:371-86. [PMID: 17501757 DOI: 10.1111/j.1365-2893.2006.00816.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
269 Dziuban EJ, Marton SA, Hughey AB, Mbingo TL, Draper HR, Schutze GE. Seroprevalence of hepatitis B in a cohort of HIV-infected children and adults in Swaziland. Int J STD AIDS 2013;24:561-5. [DOI: 10.1177/0956462413476274] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
270 He S, Li X, Li R, Fang L, Sun L, Wang Y, Wu M. Annexin A2 Modulates ROS and Impacts Inflammatory Response via IL-17 Signaling in Polymicrobial Sepsis Mice. PLoS Pathog 2016;12:e1005743. [PMID: 27389701 DOI: 10.1371/journal.ppat.1005743] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
271 Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Review of Anti-infective Therapy 2014;3:241-9. [DOI: 10.1586/14787210.3.2.241] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
272 Soriano V, Martín‐carbonero L, García‐samaniego J, Puoti M. Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus. CLIN INFECT DIS 2001;33:1793-5. [DOI: 10.1086/323009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
273 Pol S. Transplantation and viral hepatitis: major progress. Current Opinion in Organ Transplantation 2006;11:579-82. [DOI: 10.1097/mot.0b013e3280105a65] [Reference Citation Analysis]
274 Kovacs A, Karim R, Mack WJ, Xu J, Chen Z, Operskalski E, Frederick T, Landay A, Voris J, Spencer LS, Young MA, Tien PC, Augenbraun M, Strickler HD, Al-Harthi L. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010;201:823-34. [PMID: 20151840 DOI: 10.1086/650997] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
275 Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22:1979-1991. [PMID: 18784461 DOI: 10.1097/qad.0b013e32830e6d51] [Cited by in Crossref: 277] [Cited by in F6Publishing: 146] [Article Influence: 19.8] [Reference Citation Analysis]
276 Ramamurthy M, Muir AJ. Treatment of Hepatitis C in Special Populations. Clinics in Liver Disease 2006;10:851-65. [DOI: 10.1016/j.cld.2006.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
277 Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The Association of Hepatitis C Prevalence, Activity, and Genotype With HIV Infection in a Cohort of New York City Drug Users: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;33:356-64. [DOI: 10.1097/00126334-200307010-00010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
278 Fawibe AE, Olafimihan KO, Salami AK, Desalu OO, Odeigah LO. A retrospective evaluation of pretreatment and follow-up monitoring of HIV-infected adult patients in a resource-poor setting. J Int Assoc Physicians AIDS Care (Chic) 2010;9:289-91. [PMID: 20679511 DOI: 10.1177/1545109710372672] [Reference Citation Analysis]
279 Talal AH, Shata MT, Markatou M, Dorante G, Chadburn A, Koch R, Neumann AU, Ribeiro RM, Perelson AS. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr 2004;35:103-13. [PMID: 14722440 DOI: 10.1097/00126334-200402010-00001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
280 Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol. 2007;22:1510-1518. [PMID: 17645479 DOI: 10.1111/j.1440-1746.2007.05062.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
281 Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, Torres MR, Green J, Patel K. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol. 2006;36:283-291. [PMID: 16765638 DOI: 10.1016/j.jcv.2006.04.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
282 Stock PG, Fung J. Viable strategies to facilitate liver transplantation for human immunodeficiency virus coinfection. Liver Transpl 2009;15:1003-6. [PMID: 19718639 DOI: 10.1002/lt.21840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
283 Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Durant J, Ortega-Gonzalez E, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J, González-García J. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. J Antimicrob Chemother 2016;71:244-50. [PMID: 26483516 DOI: 10.1093/jac/dkv323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
284 Blackard JT, Welge JA, Taylor LE, Mayer KH, Klein RS, Celentano DD, Jamieson DJ, Gardner L, Sherman KE. HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis. 2011;52:674-680. [PMID: 21248367 DOI: 10.1093/cid/ciq199] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
285 Shafran SD. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007;44:551-6. [PMID: 17224846 DOI: 10.1097/QAI.0b013e31803151c7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
286 Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40:174-181. [PMID: 15614709 DOI: 10.1086/426021] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
287 Shiferaw MB, Tulu KT, Zegeye AM, Wubante AA. Liver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naïve HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study. AIDS Res Treat 2016;2016:1985452. [PMID: 27493798 DOI: 10.1155/2016/1985452] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
288 Duong Van Huyen J, Batisse D, Bélair M, Bruneval P. Toxicité mitochondriale hépatique associée au traitement par les antirétroviraux. Annales de Pathologie 2005;25:299-309. [DOI: 10.1016/s0242-6498(05)80134-8] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
289 Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36. [PMID: 15316335 DOI: 10.1097/00002030-200409030-00003] [Cited by in Crossref: 272] [Cited by in F6Publishing: 245] [Article Influence: 15.1] [Reference Citation Analysis]
290 Khalili M, Proietti N. Treatment of the hepatitis C virus in patients coinfected with HIV. Gastroenterology Clinics of North America 2004;33:479-96. [DOI: 10.1016/j.gtc.2004.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
291 Thomas AR, Zaman A, Bell BP. Deaths from chronic liver disease and viral hepatitis, Multnomah County, Oregon, 2000. J Clin Gastroenterol 2007;41:859-62. [PMID: 17881933 DOI: 10.1097/MCG.0b013e31802df0fe] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
292 Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, Goldie SJ. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007;120:272-9. [PMID: 17349451 DOI: 10.1016/j.amjmed.2006.06.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
293 Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis 2004;38 Suppl 2:S104-8. [PMID: 14986282 DOI: 10.1086/381453] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
294 Agbor VN, Tagny CT, Kenmegne JB, Awazi B, Ngansop C, Mbanya D, Ndembi N. Prevalence of anti-hepatitis C antibodies and its co-infection with HIV in rural Cameroon. BMC Res Notes 2018;11:459. [PMID: 29996927 DOI: 10.1186/s13104-018-3566-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
295 López-Caleya JF, Martín V, Martín L, Pérez-Simón R, Carro JA, Alcoba M. [Prevalence of coinfection by human immunodeficiency virus and hepatitis C virus in the Leon Health Area: 1992-2000]. Enferm Infecc Microbiol Clin 2006;24:365-9. [PMID: 16792937 DOI: 10.1157/13089689] [Reference Citation Analysis]
296 Kresina TF, Seeff LB, Francis H. Hepatitis C infection and injection drug use: the role of hepatologists in evolving treatment efforts. Hepatology 2004;40:516-9. [PMID: 15349886 DOI: 10.1002/hep.20367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
297 Sharma P, Rakela J. Management of pre-liver transplantation patients?Part 1. Liver Transpl 2005;11:124-33. [DOI: 10.1002/lt.20353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
298 Noska A, Liu T, Kuo I, Bazerman L, Kurth A, Coetzer M, Kantor R, Beckwith C. Validity of Self-Reported Hepatitis C Virus Status Among Criminal Justice-Involved Persons Living With HIV. J Correct Health Care 2021;27:167-71. [PMID: 34407381 DOI: 10.1089/jchc.19.05.0045] [Reference Citation Analysis]
299 Nelson M, Matthews G, Brook M, Main J; the BHIVA Coinfection Guideline Committee on behalf of the British HIV Association. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Med 2005;6:96-106. [DOI: 10.1111/j.1468-1293.2005.00300.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
300 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr HIV/AIDS Rep 2004;1:128-35. [PMID: 16091233 DOI: 10.1007/s11904-004-0019-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
301 Antoniades C, Macdonald C, Knisely A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient: HAART-Associated Mitochondrial Toxicity. Liver Transpl 2004;10:699-702. [DOI: 10.1002/lt.20109] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
302 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Current Hepatitis Reports 2002;1:16-22. [DOI: 10.1007/s11901-002-0004-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
303 Radwan D, Cachay E, Falade-Nwulia O, Moore RD, Westergaard R, Mathews WC, Aberg J, Cheever L, Gebo KA; HIV Research Network. HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015. J Acquir Immune Defic Syndr 2019;80:559-67. [PMID: 30649030 DOI: 10.1097/QAI.0000000000001949] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
304 Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S, Wallace MR. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200. [PMID: 16394852 DOI: 10.1097/01.qai.0000179459.31562.16] [Cited by in Crossref: 311] [Cited by in F6Publishing: 306] [Article Influence: 19.4] [Reference Citation Analysis]
305 Falconer K, Sandberg JK, Reichard O, Alaeus A. HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: Feasibility and results of hepatitis C treatment. Scandinavian Journal of Infectious Diseases 2009;41:881-5. [DOI: 10.3109/00365540903214272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
306 Sherman KE, Peters M, Koziel MJ. HIV and liver disease forum: conference proceedings. Hepatology 2007;45:1566-77. [PMID: 17538932 DOI: 10.1002/hep.21722] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
307 Griesbeck M, Altfeld M. Sex Differences in the Manifestations of HIV-1 Infection. In: Klein SL, Roberts CW, editors. Sex and Gender Differences in Infection and Treatments for Infectious Diseases. Cham: Springer International Publishing; 2015. pp. 103-81. [DOI: 10.1007/978-3-319-16438-0_5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
308 Trullas JC, Mocroft A, Cofan F, Tourret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J. Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr. 2010;55:582-589. [PMID: 20811290 DOI: 10.1097/qai.0b013e3181efbe59] [Cited by in Crossref: 35] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
309 Acharya C, Dharel N, Sterling RK. Chronic liver disease in the human immunodeficiency virus patient. Clin Liver Dis 2015;19:1-22. [PMID: 25454294 DOI: 10.1016/j.cld.2014.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
310 Cooper CL. Therapies for HIV and viral hepatitis coinfection. Expert Rev Anti Infect Ther 2005;3:81-9. [PMID: 15757459 DOI: 10.1586/14787210.3.1.81] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
311 Mohammed DY, Martin E, Sadashige C, Jaker M, Paul S. An anonymous unlinked sero-prevalence survey of HIVHCV in an urban Emergency Department. Journal of Clinical Virology 2013;58:e19-23. [DOI: 10.1016/j.jcv.2013.08.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
312 Franceschini N, Napravnik S, Eron JJ Jr, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005;67:1526-31. [PMID: 15780107 DOI: 10.1111/j.1523-1755.2005.00232.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 109] [Article Influence: 7.6] [Reference Citation Analysis]
313 Pace FHDL, Ferreira LEVDC, Silva AEB, Ferraz MLG. Liver fibrosis progression in HIV/hepatitis C virus coinfected patients with normal aminotransferases levels. Rev Soc Bras Med Trop 2012;45:444-7. [DOI: 10.1590/s0037-86822012000400005] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
314 Stebbing J, Wong N, Tan L, Scourfield A, Jiao LR, Shousha S, Grover D, Bower M, Nelson M. The relationship between prolonged antiretroviral therapy and cryptogenic liver disease. J Acquir Immune Defic Syndr. 2009;50:554-556. [PMID: 19300102 DOI: 10.1097/QAI.0b013e31819c338f] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
315 Braitstein P, Yip B, Montessori V, Moore D, Montaner JS, Hogg RS. Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients. CMAJ 2005;173:160-4. [PMID: 16027432 DOI: 10.1503/cmaj.045202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
316 Mcgovern B, Fiore J, Wurcel A, Taglienti P, Bradley M, Galvin S, Libone G, Ramsey J, Molinaro-gudas V, Drewniak S, Amick C, Andalkar A, Scheft H, Bica I. Delivering Therapy for Hepatitis C Virus Infection to Incarcerated HIV-Seropositive Patients. Clinical Infectious Diseases 2005;41:S56-62. [DOI: 10.1086/429497] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
317 Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, Vazquez-Chacon C, Martinez-Guarneros A, Carpio-Pedroza JC, Fonseca-Coronado S, Cruz-Rivera M. Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World J Gastroenterol 2014; 20(43): 15992-16013 [PMID: 25473152 DOI: 10.3748/wjg.v20.i43.15992] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
318 Rodríguez-Vidigal FF, Habernau A. [Cause of hospitalization in patients with human immunodeficiency virus infection in a rural area. Role of chronic liver disease]. Enferm Infecc Microbiol Clin 2004;22:138-41. [PMID: 14987533 DOI: 10.1016/s0213-005x(04)73053-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
319 Fishbein DA, Lo Y, Netski D, Thomas DL, Klein RS. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J Acquir Immune Defic Syndr. 2006;41:471-476. [PMID: 16652056 DOI: 10.1097/01.qai.0000218360.28712.f3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
320 Montes Ramírez ML, Miró JM, Quereda C, Jou A, von Wichmann MÁ, Berenguer J, González-García JJ, Hernando A, Ortega E, Sanz J. Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. J Acquir Immune Defic Syndr. 2014;65:82-86. [PMID: 24419065 DOI: 10.1097/qai.0b013e3182a685dc] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
321 Shastry L, Wilson T, Lascher S, Nord JA. The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients. AIDS 2007;21:2541-3. [PMID: 18025895 DOI: 10.1097/QAD.0b013e3282f1fe59] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
322 Jain MK. Drug-induced liver injury associated with HIV medications. Clin Liver Dis 2007;11:615-39, vii-viii. [PMID: 17723923 DOI: 10.1016/j.cld.2007.06.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
323 Bonnet F, Morlat P, Chêne G, Mercié P, Neau D, Chossat I, Decoin M, Djossou F, Beylot J, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002;3:195-9. [PMID: 12139658 DOI: 10.1046/j.1468-1293.2002.00117.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 3.2] [Reference Citation Analysis]
324 Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database Syst Rev 2010;:CD004888. [PMID: 20091566 DOI: 10.1002/14651858.CD004888.pub2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
325 Maier MM, He H, Schafer SD, Ward TT, Zaman A. Hepatitis C treatment eligibility among HIV-hepatitis C virus coinfected patients in Oregon: a population-based sample. AIDS Care 2014;26:1178-85. [PMID: 24601687 DOI: 10.1080/09540121.2014.892563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
326 Shire NJ, Horn PS, Rouster SD, Stanford S, Eyster ME, Sherman KE; Multicenter Hemophilia Cohort HCV Study Group. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology 2006;44:1146-57. [PMID: 17058240 DOI: 10.1002/hep.21374] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
327 Adekunle RO, DeSilva K, Cartwright EJ. Hepatitis C Care Continuum in a Human Immunodeficiency Virus (HIV) Positive Cohort: Data From the HIV Atlanta Veterans Affairs Cohort Study. Open Forum Infect Dis 2020;7:ofaa085. [PMID: 32280724 DOI: 10.1093/ofid/ofaa085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
328 Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT; Aids Clinical Trials Group A5178 Study Team. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One 2011;6:e25753. [PMID: 22003405 DOI: 10.1371/journal.pone.0025753] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
329 Sarmento-castro R, Horta A, Vasconcelos O, Coelho H, Mendez J, Tavares AP, Seabra J, Duarte M, Chaves L, Fortes O, Recalde C, Ventura Â, Pires N, Pinho L, Dias N, Carneiro F. Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV–HIV co-infection. Journal of Infection 2007;54:609-16. [DOI: 10.1016/j.jinf.2006.11.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
330 Núñez M, Soriano V. Current concepts in the management and treatment of hepatitis C in HIV-infected patients. Annals of Hepatology 2005;4:151-60. [DOI: 10.1016/s1665-2681(19)32060-5] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
331 Ocama P, Nambooze S, Opio CK, Shiels MS, Wabinga HR, Kirk GD. Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005. Br J Cancer 2009;100:799-802. [PMID: 19174820 DOI: 10.1038/sj.bjc.6604893] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
332 Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. J Viral Hepat 2008;15:482-9. [PMID: 18221297 DOI: 10.1111/j.1365-2893.2008.00969.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
333 Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Clin Infect Dis 2016;62:1489-96. [PMID: 27025835 DOI: 10.1093/cid/ciw163] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
334 Mastroianni CM, Liuzzi GM, D'Ettorre G, Lichtner M, Forcina G, Di Campli NF, Riccio P, Vullo V. Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV. HIV Clin Trials. 2002;3:310-315. [PMID: 12187505 DOI: 10.1310/u9lj-mff9-are1-257h] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
335 Núñez M, Soriano V. Risks and benefits of antiretroviral therapy in HIV–HCV co-infected patients. Journal of Hepatology 2005;42:290-2. [DOI: 10.1016/j.jhep.2004.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
336 Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Bräu N, Hatzakis A, Pol S. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-1089. [PMID: 17502718 DOI: 10.1097/qad.0b013e3281084e4d] [Cited by in Crossref: 238] [Cited by in F6Publishing: 60] [Article Influence: 15.9] [Reference Citation Analysis]
337 Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol. 2009;83:7366-7374. [PMID: 19420073 DOI: 10.1128/jvi.00191-09] [Cited by in Crossref: 89] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
338 Moreno L, Quereda C, Moreno A, Perez-elías MJ, Antela A, Casado JL, Dronda F, Mateos ML, Bárcena R, Moreno S. Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients: . AIDS 2004;18:67-73. [DOI: 10.1097/00002030-200401020-00008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.3] [Reference Citation Analysis]
339 Vargas JI, Jensen D, Sarmiento V, Peirano F, Acuña P, Fuster F, Soto S, Ahumada R, Huilcaman M, Bruna M, Jensen W, Fuster F. Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile. J Med Virol 2016;88:639-46. [PMID: 26381185 DOI: 10.1002/jmv.24384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
340 Sterling RK, Contos MJ, Sanyal AJ, Luketic VA, Stravitz RT, Wilson MS, Mills AS, Shiffman ML. The Clinical Spectrum of Hepatitis C Virus in HIV Coinfection: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;32:30-7. [DOI: 10.1097/00126334-200301010-00005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
341 Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, Fisher M, Johnson AM, Dusheiko GM. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983-91. [DOI: 10.1097/qad.0b013e3281053a0c] [Cited by in Crossref: 304] [Cited by in F6Publishing: 115] [Article Influence: 20.3] [Reference Citation Analysis]
342 Yeo T, Kintner J, Armand R, Perez R, Lewis L. Sublethal concentrations of gemcitabine (2′,2′-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells. Hum Exp Toxicol 2007;26:911-21. [DOI: 10.1177/0960327107086513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
343 Pau AK. Antiretroviral Therapy-associated Serious and Life-threatening Toxicities. Curr Infect Dis Rep 2003;5:429-38. [PMID: 13678573 DOI: 10.1007/s11908-003-0023-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
344 Capa L, Soriano V, García-Samaniego J, Nuñez M, Romero M, Cascajero A, Muñoz F, González-Lahoz J, Benito JM. Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus. J Med Virol 2007;79:503-10. [PMID: 17385690 DOI: 10.1002/jmv.20856] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
345 Guitton E, Montastruc J, Lapeyre-mestre M; The French Network of Pharmacovigilance Centres. Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol 2006;62:243-9. [DOI: 10.1007/s00228-005-0080-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
346 Haverkamp M, Smit M, Weersink A, Boucher CA, Hoepelman AI. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count). AIDS 2003;17:1572-4. [PMID: 12824802 DOI: 10.1097/00002030-200307040-00023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
347 Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, Bonet L, Vidal F, Milinkovic A, Bassa A. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22-31. [PMID: 19085908 DOI: 10.1002/hep.22598] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 6.2] [Reference Citation Analysis]
348 Aloise R, de Almeida AJ, Sion FS, Morais-de-Sá CA, Gaspar AM, de Paula VS. Changes in hepatitis A virus seroepidemiology in HIV-infected Brazilian patients. Int J STD AIDS 2008;19:321-6. [PMID: 18482962 DOI: 10.1258/ijsa.2007.007100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
349 Soriano V, Martín-carbonero L, García-samaniego J. Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS 2003;17:751-3. [DOI: 10.1097/00002030-200303280-00015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
350 Leen CL. Hepatitis C and HIV co-infection. Int J STD AIDS 2004;15:289-94; quiz 295. [PMID: 15117493 DOI: 10.1177/095646240401500502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
351 Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol 2010;39:1162-9. [PMID: 19786463 DOI: 10.1093/ije/dyp297] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
352 Dahari H, Affonso de Araujo ES, Haagmans BL, Layden TJ, Cotler SJ, Barone AA, Neumann AU. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol 2010;53:460-7. [PMID: 20561702 DOI: 10.1016/j.jhep.2010.03.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
353 Rauch A, Egger M, Reichen J, Furrer H. Chronic Hepatitis C in HIV-Infected Patients: Low Eligibility and Applicability of Therapy With Pegylated Interferon-?? Plus Ribavirin: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2005;38:238-40. [DOI: 10.1097/01.qai.0000148535.97081.72] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
354 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
355 Michel L, Giorgi R, Villes V, Poizot-martin I, Dellamonica P, Spire B, Protopopescu C, Carrieri MP. Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART). Drug and Alcohol Dependence 2009;99:96-104. [DOI: 10.1016/j.drugalcdep.2008.07.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
356 Baranoski AS, Cotton D, Heeren T, Nunes D, Kubiak RW, Horsburgh CR Jr. Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men. Open Forum Infect Dis 2016;3:ofv214. [PMID: 26955643 DOI: 10.1093/ofid/ofv214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
357 Righi E, Ivaldi F, La Rosa A, Carnelutti A, Londero A, Bassetti M. Immunological profiles of HIV-positive recipients of liver transplant. Transpl Immunol 2019;57:101208. [PMID: 31102654 DOI: 10.1016/j.trim.2019.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
358 Bhardwaj S, Ahmad F, Wedemeyer H, Cornberg M, Schulze Zur Wiesch J, van Lunzen J, Sarin SK, Schmidt RE, Meyer-Olson D. Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype. Virol J. 2016;13:67. [PMID: 27091211 DOI: 10.1186/s12985-016-0507-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
359 Otedo A, Simbiri KO, Were V, Ongati O, Estambale BA. Risk factors for liver Cancer in HIV endemic areas of Western Kenya.Infect Agent Cancer. 2018;13:41. [PMID: 30607173 DOI: 10.1186/s13027-018-0214-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
360 McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43:365-372. [PMID: 16804853 DOI: 10.1086/505495] [Cited by in Crossref: 121] [Cited by in F6Publishing: 105] [Article Influence: 7.6] [Reference Citation Analysis]
361 Fernandez-Botran R, Joshi-Barve S, Ghare S, Barve S, Young M, Plankey M, Bordon J. Systemic cytokine and interferon responsiveness Patterns in HIV and HCV mono and co-infections. J Interferon Cytokine Res 2014;34:885-93. [PMID: 24955730 DOI: 10.1089/jir.2014.0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
362 Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). The Lancet 2002;360:1921-6. [DOI: 10.1016/s0140-6736(02)11913-1] [Cited by in Crossref: 686] [Cited by in F6Publishing: 281] [Article Influence: 34.3] [Reference Citation Analysis]
363 Puri P, Kumar S. Liver involvement in human immunodeficiency virus infection. Indian J Gastroenterol 2016;35:260-73. [DOI: 10.1007/s12664-016-0666-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
364 Cacoub P, Halfon P, Rosenthal E, Pialoux G, Benhamou Y, Perronne C, Pol S; Prospecth Study Group. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol 2008;48:35-42. [PMID: 17945375 DOI: 10.1016/j.jhep.2007.07.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
365 Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc 2011;14:22. [PMID: 21548988 DOI: 10.1186/1758-2652-14-22] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
366 Abdel-Hameed EA, Rouster SD, Zhang X, Chen J, Medvedovic M, Goodman ZD, Sherman KE. Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis. J Acquir Immune Defic Syndr 2017;74:353-8. [PMID: 27898525 DOI: 10.1097/QAI.0000000000001256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
367 Sánchez-Conde M, Montes-Ramírez ML, Miralles P, Alvarez JM, Bellón JM, Ramírez M, Arribas JR, Gutiérrez I, López JC, Cosín J. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 2010;17:280-286. [PMID: 19732322 DOI: 10.1111/j.1365-2893.2009.01180.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 5.9] [Reference Citation Analysis]
368 Sun CJ, Tobin K, Spikes P, Latkin C. Correlates of same-sex behavior disclosure to health care providers among Black MSM in the United States: implications for HIV prevention. AIDS Care 2019;31:1011-8. [PMID: 30449137 DOI: 10.1080/09540121.2018.1548753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
369 Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol. 2005;100:2338-2354. [PMID: 16181388 DOI: 10.1111/j.1572-0241.2005.00222.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 3.3] [Reference Citation Analysis]
370 Pessôa MG, Gazzard B, Huang AK, Brandão-mello CE, Cassetti I, Mendes-corrêa MC, Soriano V, Phiri P, Hall A, Brett-smith H. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008;22:1779-87. [DOI: 10.1097/qad.0b013e32830b3ab5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
371 Torgersen J, So-Armah K, Freiberg MS, Goetz MB, Budoff MJ, Lim JK, Taddei T, Butt AA, Rodriguez-Barradas MC, Justice AC, Kostman JR, Lo Re V 3rd. Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. BMC Gastroenterol 2019;19:52. [PMID: 30987601 DOI: 10.1186/s12876-019-0969-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
372 Kew MC. Hepatitis B virus / human immunodeficiency virus co-infection and its hepatocarcinogenic potential in sub-saharan black africans. Hepat Mon 2012;12:e7876. [PMID: 23166538 DOI: 10.5812/hepatmon.7876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
373 Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 2005;19 Suppl 3:S179-89. [PMID: 16251816 DOI: 10.1097/01.aids.0000192088.72055.90] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
374 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2001;3:469-76. [DOI: 10.1007/bf03160472] [Cited by in Crossref: 27] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
375 Penton PK, Blackard JT. Analysis of HIV quasispecies suggests compartmentalization in the liver. AIDS Res Hum Retroviruses 2014;30:394-402. [PMID: 24074301 DOI: 10.1089/AID.2013.0146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
376 Eisenbach C, Merle U, Stremmel W, Encke J. Liver transplantation in HIV-positive patients. Clin Transplant. 2009;23 Suppl 21:68-74. [PMID: 19930319 DOI: 10.1111/j.1399-0012.2009.01112.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
377 Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, Kim SS, Borges CB, Shao RX, Chung RT. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology. 2008;134:803-811. [PMID: 18325393 DOI: 10.1053/j.gastro.2008.01.005] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 7.6] [Reference Citation Analysis]
378 Amin J, Kaye M, Skidmore S, Pillay D, Cooper D, Dore G. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004;5:174-9. [DOI: 10.1111/j.1468-1293.2004.00207.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 4.3] [Reference Citation Analysis]
379 Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803-1809. [PMID: 12891066 DOI: 10.1097/00002030-200308150-00009] [Cited by in Crossref: 189] [Cited by in F6Publishing: 171] [Article Influence: 9.9] [Reference Citation Analysis]
380 Rakela J. Hepatitis C: Magnitude of the problem. Liver Transplantation 2002;8:S3-6. [DOI: 10.1053/jlts.2002.35855] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
381 Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, Heeren T, Koziel M, Graham C, Craven DE, Stuver S, Horsburgh CR Jr. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr. 2005;40:538-544. [PMID: 16284529 DOI: 10.1097/01.qai.0000184856.31695.bf] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 4.9] [Reference Citation Analysis]
382 Thibault PA, Wilson JA. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol Res 2013;75:48-59. [PMID: 23541631 DOI: 10.1016/j.phrs.2013.03.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
383 Kaur I, Gupta RC, Puri M. Ribosome inactivating proteins from plants inhibiting viruses. Virol Sin 2011;26:357-65. [PMID: 22160935 DOI: 10.1007/s12250-011-3223-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
384 Alatrakchi N, Koziel MJ. A tale of two viruses: hepatitis C in the age of HAART. The Lancet 2003;362:1687-8. [DOI: 10.1016/s0140-6736(03)14881-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
385 Fung SK, Lok AS. Update on viral hepatitis in 2004. Curr Opin Gastroenterol 2005;21:300-7. [PMID: 15818150 DOI: 10.1097/01.mog.0000158109.13722.36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
386 Dieterich D. Treatment of Hepatitis C and Anemia in Human Immunodeficiency Virus–Infected Patients. J INFECT DIS 2002;185:S128-37. [DOI: 10.1086/340199] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
387 Murphy MJ, Wilcox RD. Management of the coinfected patient: human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C. Am J Med Sci 2004;328:26-36. [PMID: 15254439 DOI: 10.1097/00000441-200407000-00005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
388 Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. BMC Res Notes 2012;5:180. [PMID: 22490728 DOI: 10.1186/1756-0500-5-180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
389 Gupta A, Swaminathan G, Martin-Garcia J, Navas-Martin S. MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy. Viruses 2012;4:2485-513. [PMID: 23202492 DOI: 10.3390/v4112485] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
390 Norris S, Houlihan D. Liver transplantation in HIV-positive patients. Expert Review of Gastroenterology & Hepatology 2014;2:39-46. [DOI: 10.1586/17474124.2.1.39] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
391 Keiser O, Taffé P, Zwahlen M, Battegay M, Bernasconi E, Weber R, Rickenbach M. All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population: . AIDS 2004;18:1835-43. [DOI: 10.1097/00002030-200409030-00013] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 3.4] [Reference Citation Analysis]
392 Kim J, Jung Y. Potential role of thymosin Beta 4 in liver fibrosis. Int J Mol Sci 2015;16:10624-35. [PMID: 26006229 DOI: 10.3390/ijms160510624] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
393 Hughes CA, Shafran SD. Treatment of hepatitis C in HIV-coinfected patients. Ann Pharmacother 2006;40:479-89; quiz 582-3. [PMID: 16507622 DOI: 10.1345/aph.1G427] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
394 Schreibman I, Gaynor JJ, Jayaweera D, Pyrsopoulos N, Weppler D, Tzakis A, Schiff ER, Regev A. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation. 2007;84:697-705. [PMID: 17893602 DOI: 10.1097/01.tp.0000282873.24648.5b] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
395 Thomas DL. Growing importance of liver disease in HIV-infected persons. Hepatology 2006;43:S221-9. [DOI: 10.1002/hep.21033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
396 Weiss JJ, Konstantinidis I, Boueilh A, Fierer DS, Gardenier D, Barber MG, Kang T, Kress A, Ericson K, Lira MC, Yostos MP, Bogner HR, Wisnivesky JP, Wyatt CM. Illness Perceptions, Medication Beliefs, and Adherence to Antiretrovirals and Medications for Comorbidities in Adults With HIV Infection and Hypertension or Chronic Kidney Disease. J Acquir Immune Defic Syndr 2016;73:403-10. [PMID: 27171742 DOI: 10.1097/QAI.0000000000001075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
397 Ristig M, Drechsler H, Crippin J, Lisker-melman M, Tebas P. Management of Chronic Hepatitis B in an HIV-Positive Patient with 3TC-Resistant Hepatitis B Virus. AIDS Patient Care and STDs 2003;17:439-42. [DOI: 10.1089/108729103322395456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
398 Raizada A, Dwivedi S, Bhattacharya S. Hepatitis B, hepatitis C and HIV co-infection at an antiretroviral centre in Delhi. Trop Doct 2011;41:154-6. [PMID: 21586511 DOI: 10.1258/td.2011.100440] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
399 Osilla KC, Wagner G, Garnett J, Ghosh-Dastidar B, Witt M, Bhatti L, Goetz MB. Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment. AIDS Patient Care STDS. 2011;25:533-538. [PMID: 21823907 DOI: 10.1089/apc.2011.0048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
400 Vellozzi C, Buchacz K, Baker R, Spradling PR, Richardson J, Moorman A, Tedaldi E, Durham M, Ward J, Brooks JT. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. J Viral Hepat. 2011;18:316-324. [PMID: 20367803 DOI: 10.1111/j.1365-2893.2010.01299.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
401 Backus LI, Boothroyd DB, Phillips BR, Mole LA. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. J Viral Hepat. 2006;13:799-810. [PMID: 17109679 DOI: 10.1111/j.1365-2893.2006.00751.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
402 Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH. IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients. J Acquir Immune Defic Syndr 2013;63:9-16. [PMID: 23274935 DOI: 10.1097/QAI.0b013e31828323c1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
403 Jahangiri B, Haddad H. Cardiac transplantation in HIV-positive patients: are we there yet? J Heart Lung Transplant 2007;26:103-7. [PMID: 17258141 DOI: 10.1016/j.healun.2006.11.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
404 Anadol E, Beckebaum S, Radecke K, Paul A, Zoufaly A, Bickel M, Hitzenbichler F, Ganten T, Kittner J, Stoll M. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS Res Treat. 2012;2012:197501. [PMID: 22900154 DOI: 10.1155/2012/197501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
405 Gebo KA, Diener-west M, Moore RD. Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV Cohort: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;34:165-73. [DOI: 10.1097/00126334-200310010-00006] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 3.8] [Reference Citation Analysis]
406 Tanaka Y, Hanada K, Hanabusa H, Kurbanov F, Gojobori T, Mizokami M. Increasing genetic diversity of hepatitis C virus in haemophiliacs with human immunodeficiency virus coinfection. J Gen Virol. 2007;88:2513-2519. [PMID: 17698661 DOI: 10.1099/vir.0.82974-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
407 Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity Associated with Antiretroviral Therapy Containing Dual versus Single Protease Inhibitors in Individuals Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus. CLIN INFECT DIS 2002;34:1259-63. [DOI: 10.1086/339867] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
408 Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. Vaccine. 2006;24:272-279. [PMID: 16139398 DOI: 10.1016/j.vaccine.2005.07.102] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
409 Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol. 2006;44:S28-S34. [PMID: 16343684 DOI: 10.1016/j.jhep.2005.11.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
410 Tahiri M, Sodqi M, Lahdami FEZ, Marih L, Lamdini H, Hliwa W, Lahcen AO, Badre W, Haddad F, Chakib A, Bellabah A, Alaoui R, Filali KME. Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco. World J Hepatol 2013; 5(10): 584-588 [PMID: 24179618 DOI: 10.4254/wjh.v5.i10.584] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
411 Thio CL. Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: Is adefovir dipivoxil the answer? Journal of Hepatology 2006;44:1-3. [DOI: 10.1016/j.jhep.2005.10.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
412 Murillas J, Del Río M, Riera M, Vaquer P, Salas A, Leyes M, Angeles Ribas M, Peñaranda Vera M, Villalonga C. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. European Journal of Internal Medicine 2005;16:113-5. [DOI: 10.1016/j.ejim.2004.09.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
413 Koike K, Kikuchi Y, Kato M, Takamatsu J, Shintani Y, Tsutsumi T, Fujie H, Miyoshi H, Moriya K, Yotsuyanagi H. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 2008;38:310-4. [PMID: 17877726 DOI: 10.1111/j.1872-034X.2007.00263.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
414 Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE; Actg A5178 Study Team. Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials 2012;13:70-82. [PMID: 22510354 DOI: 10.1310/hct1302-70] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
415 Assimakopoulos SF, Dimitropoulou D, Marangos M, Gogos CA. Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies. Infection 2014;42:951-9. [PMID: 25070877 DOI: 10.1007/s15010-014-0666-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
416 Marchetti G, Nasta P, Bai F, Gatti F, Bellistrì GM, Tincati C, Borghi F, Carosi G, Puoti M, Monforte Ad. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PLoS One. 2012;7:e32028. [PMID: 22363790 DOI: 10.1371/journal.pone.0032028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
417 Wagner GJ, Ryan GW. Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness. AIDS. 2005;19 Suppl 3:S190-S198. [PMID: 16251817 DOI: 10.1097/01.aids.0000192089.54130.b6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
418 Levine RS, Briggs NC, Kilbourne BS, King WD, Fry-Johnson Y, Baltrus PT, Husaini BA, Rust GS. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health 2007;97:1884-92. [PMID: 17761583 DOI: 10.2105/AJPH.2005.081489] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
419 Crum-Cianflone N, Collins G, Medina S, Asher D, Campin R, Bavaro M, Hale B, Hames C. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol. 2010;8:183-191. [PMID: 19800985 DOI: 10.1016/j.cgh.2009.09.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
420 Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, Wiselka M, Norris S. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52:1035-40. [PMID: 12801963 DOI: 10.1136/gut.52.7.1035] [Cited by in Crossref: 180] [Cited by in F6Publishing: 170] [Article Influence: 9.5] [Reference Citation Analysis]
421 Collins LF, Chan A, Zheng J, Chow SC, Wilder JM, Muir AJ, Naggie S. Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection. Open Forum Infect Dis 2018;5:ofx264. [PMID: 29308413 DOI: 10.1093/ofid/ofx264] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
422 Jansson J, Wilson DP. Projected demographic profile of people living with HIV in Australia: planning for an older generation. PLoS One 2012;7:e38334. [PMID: 22912660 DOI: 10.1371/journal.pone.0038334] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
423 Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407-413. [PMID: 19575364 DOI: 10.1002/hep.23020] [Cited by in Crossref: 227] [Cited by in F6Publishing: 214] [Article Influence: 17.5] [Reference Citation Analysis]
424 Cainelli F, Concia E, Vento S. Mortality Due to Hepatitis C Virus–Related Cirrhosis in Patients Infected with HIV Type 1: A Role for Alcohol. CLIN INFECT DIS 2001;33:1795-6. [DOI: 10.1086/323011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
425 Klein MB, Cooper C, Brouillette MJ, Sheehan NL, Benkelfat C, Annable L, Weston F, Kraus D, Singer J. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials. 2008;29:617-630. [PMID: 18262853 DOI: 10.1016/j.cct.2008.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
426 Moreno S, Fortún J, Quereda C, Moreno A, Pérez-elías MJ, Martín-dávila P, de Vicente E, Bárcena R, Quijano Y, García M, Nuño J, Martínez A. Liver transplantation in HIV-infected recipients: Liver Transplantation in HIV Infection. Liver Transpl 2005;11:76-81. [DOI: 10.1002/lt.20318] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
427 Khan MM, Tait RC, Kerr R, Ludlam CA, Lowe GDO, Murray W, Watson HG. Hepatitis C infection and outcomes in the Scottish haemophilia population. Haemophilia 2013;19:870-5. [DOI: 10.1111/hae.12218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
428 Kresina TF, Flexner CW, Sinclair J, Correia MA, Stapleton JT, Adeniyi-jones S, Cargill V, Cheever LW. Alcohol Use and HIV Pharmacotherapy. AIDS Research and Human Retroviruses 2002;18:757-70. [DOI: 10.1089/08892220260139495] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.3] [Reference Citation Analysis]
429 Devlin KN, Gongvatana A, Clark US, Chasman JD, Westbrook ML, Tashima KT, Navia B, Cohen RA. Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc 2012;18:68-78. [PMID: 22132928 DOI: 10.1017/S1355617711001408] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
430 Kemmer N, Neff GW. Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int. 2007;27:1297-1310. [PMID: 18036096 DOI: 10.1111/j.1478-3231.2007.01613.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
431 Thakarar K, Asiimwe SB, Cheng DM, Forman L, Ngabirano C, Muyindike WR, Emenyonu NI, Samet JH, Hahn JA. Alcohol Consumption in Ugandan HIV-Infected Household-Brewers Versus Non-Brewers. AIDS Behav 2016;20:2408-17. [PMID: 27150894 DOI: 10.1007/s10461-016-1421-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
432 Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002;36:S201-S209. [PMID: 12407595 DOI: 10.1002/hep.1840360726] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
433 Laskus T, Kibler KV, Chmielewski M, Wilkinson J, Adair D, Horban A, Stańczak G, Radkowski M. Effect of hepatitis C infection on HIV-induced apoptosis. PLoS One 2013;8:e75921. [PMID: 24098405 DOI: 10.1371/journal.pone.0075921] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
434 Akgün KM, Pisani M, Crothers K. The changing epidemiology of HIV-infected patients in the intensive care unit. J Intensive Care Med 2011;26:151-64. [PMID: 21436170 DOI: 10.1177/0885066610387996] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
435 Johnson TM, Sison R, Fallon JP, Shukla PP, Bhattarai S, Galang H, Habeeb R, Slim J. Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy. HIV Clin Trials 2016;17:242-5. [PMID: 27846791 DOI: 10.1080/15284336.2016.1248625] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
436 Sidiq H, Ankoma-sey V. HIV-Related Liver Disease: Infections Versus Drugs. Gastroenterology Clinics of North America 2006;35:487-505. [DOI: 10.1016/j.gtc.2006.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
437 Roland ME, Adey D, Carlson LL, Terrault NA. Kidney and Liver Transplantation in HIV-Infected Patients: Case Presentations and Review. AIDS Patient Care and STDs 2003;17:501-7. [DOI: 10.1089/108729103322494294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
438 Reiberger T, Rasoul-Rockenschaub S, Rieger A, Ferenci P, Gangl A, Peck-Radosavljevic M. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. Eur J Clin Invest 2008;38:421-9. [PMID: 18489402 DOI: 10.1111/j.1365-2362.2008.01958.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
439 Asmal M, Seaman M, Lin W, Chung RT, Letvin NL, Geiben-Lynn R. Inhibition of HCV by the serpin antithrombin III. Virol J 2012;9:226. [PMID: 23031791 DOI: 10.1186/1743-422X-9-226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
440 Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013;27:2551-2557. [PMID: 23736152 DOI: 10.1097/qad.0b013e32836381cc] [Cited by in Crossref: 131] [Cited by in F6Publishing: 61] [Article Influence: 16.4] [Reference Citation Analysis]
441 Fuster D, Tsui JI, Cheng DM, Quinn EK, Armah KA, Nunes D, Freiberg MS, Samet JH. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. AIDS Res Hum Retroviruses. 2013;29:1110-1116. [PMID: 23601055 DOI: 10.1089/aid.2012.0348] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
442 Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. The Lancet Infectious Diseases 2007;7:402-9. [DOI: 10.1016/s1473-3099(07)70135-4] [Cited by in Crossref: 201] [Cited by in F6Publishing: 89] [Article Influence: 13.4] [Reference Citation Analysis]
443 Justice AC, McGinnis KA, Skanderson M, Chang CC, Gibert CL, Goetz MB, Rimland D, Rodriguez-Barradas MC, Oursler KK, Brown ST, Braithwaite RS, May M, Covinsky KE, Roberts MS, Fultz SL, Bryant KJ; VACS Project Team. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med 2010;11:143-51. [PMID: 19751364 DOI: 10.1111/j.1468-1293.2009.00757.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 118] [Article Influence: 8.8] [Reference Citation Analysis]
444 Mallolas Masferrer J, Martínez-rebollar M, Laguno Centeno M. Tratamiento de la hepatitis por virus C en pacientes coinfectados por el virus de la inmunodeficiencia humana. Gastroenterología y Hepatología 2011;34:558-67. [DOI: 10.1016/j.gastrohep.2011.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
445 Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine. 2010;28:5597-5604. [PMID: 20600512 DOI: 10.1016/j.vaccine.2010.06.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
446 de Lédinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, Dhumeaux D, Beaugrand M. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41:175-179. [PMID: 16394849 DOI: 10.1097/01.qai.0000194238.15831.c7] [Cited by in Crossref: 245] [Cited by in F6Publishing: 242] [Article Influence: 15.3] [Reference Citation Analysis]
447 Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. Int J Infect Dis 2009;13:302-6. [PMID: 19004656 DOI: 10.1016/j.ijid.2008.06.042] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
448 Ristig MB, Tebas P, Gandy I, Qaqish R, Aberg JA. Cure of Acute Hepatitis C in HIV Co-infection?: . Journal of Clinical Gastroenterology 2004;38:303. [DOI: 10.1097/00004836-200403000-00026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
449 Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, De Paoli P, Lleshi A, Izzi I, Torresin A. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist. 2011;16:1258-1269. [PMID: 21868692 DOI: 10.1634/theoncologist.2010-0400] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
450 Moylan CA, Muir AJ. Treatment of hepatitis C in special populations. Clin Liver Dis 2005;9:567-77, v. [PMID: 16207564 DOI: 10.1016/j.cld.2005.07.005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
451 Talal AH, Canchis PW, Jacobson IM. The HCV and HIV coinfected patient: What have we learned about pathophysiology? Curr Gastroenterol Rep 2002;4:15-22. [DOI: 10.1007/s11894-002-0033-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
452 Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS. 2011;6:514-526. [PMID: 22001895 DOI: 10.1097/coh.0b013e32834b54dc] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
453 Kanwal F, Gralnek IM, Hays RD, Dulai GS, Spiegel BM, Bozzette S, Asch S. Impact of Chronic Viral Hepatitis on Health-Related Quality of Life in HIV: Results from a Nationally Representative Sample. Am J Gastroenterology 2005;100:1984-94. [DOI: 10.1111/j.1572-0241.2005.41962.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
454 Bräu N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003;17:2279-90. [DOI: 10.1097/00002030-200311070-00002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
455 Kobayashi T, Yasuno T, Takahashi K, Nakamura S, Mashino T, Ohe T. Novel pyridinium-type fullerene derivatives as multitargeting inhibitors of HIV-1 reverse transcriptase, HIV-1 protease, and HCV NS5B polymerase. Bioorg Med Chem Lett 2021;49:128267. [PMID: 34271071 DOI: 10.1016/j.bmcl.2021.128267] [Reference Citation Analysis]
456 Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr. 2008;47:221-225. [PMID: 18223361 DOI: 10.1097/qai.0b013e31815d2f59] [Cited by in Crossref: 58] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
457 Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study. The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat 2010;17:569-77. [PMID: 19840365 DOI: 10.1111/j.1365-2893.2009.01215.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
458 Chang PE, Miquel R, Blanco JL, Laguno M, Bruguera M, Abraldes JG, Bosch J, Garcia-Pagan JC. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol. 2009;104:1707-1714. [PMID: 19471257 DOI: 10.1038/ajg.2009.165] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
459 Feld JJ, Liang TJ. Hepatitis C — identifying patients with progressive liver injury. Hepatology 2006;43:S194-206. [DOI: 10.1002/hep.21065] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 3.9] [Reference Citation Analysis]
460 Barril G, Trullás J, González-parra E, Moreno A, Bergada E, Jofre R, Martínez-ara J, de Sequera P, Ángel Oliver J, Arrieta J, Miró JM. Prevalencia de la infección por el VIH en centros de diálisis en España y potenciales candidatos para trasplante renal: resultados de una encuesta española. Enfermedades Infecciosas y Microbiología Clínica 2005;23:335-9. [DOI: 10.1157/13076172] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
461 Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health. 2004;81:25-37. [PMID: 15047781 DOI: 10.1093/jurban/jth085] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 5.6] [Reference Citation Analysis]
462 Mendes-Corrêa MC, Andrade HF Jr, Fumica Takakura C, Seixas Duarte MI. Hepatic ultrastructural mitochondrial changes prior to antiretroviral therapy in HIV-infected patients in Brazil. J Int Assoc Physicians AIDS Care (Chic) 2008;7:252-8. [PMID: 18626121 DOI: 10.1177/1545109708321860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
463 Adih WK, Selik RM, Hu X. Trends in Diseases Reported on US Death Certificates That Mentioned HIV Infection, 1996-2006. J Int Assoc Physicians AIDS Care (Chic). 2011;10:5-11. [PMID: 21088284 DOI: 10.1177/1545109710384505] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
464 Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, Gazzard BG, Nelson MR. Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 2005;40:41-6. [DOI: 10.1097/01.qai.0000174930.64145.a9] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 5.4] [Reference Citation Analysis]
465 Mohsen AH, Easterbrook P, Taylor CB, Norris S. Hepatitis C and HIV-1 coinfection. Gut 2002;51:601-8. [PMID: 12235089 DOI: 10.1136/gut.51.4.601] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 3.0] [Reference Citation Analysis]
466 Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R, Reynolds HE, Garazzino S, Sinicco A, Khoo SH, Back DJ, Di Perri G. The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests. AIDS Research and Human Retroviruses 2004;20:716-22. [DOI: 10.1089/0889222041524670] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
467 Spradling PR, Richardson JT, Buchacz K, Moorman AC, Finelli L, Bell BP, Brooks JT; HIV Outpatient Study Investigators. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr 2010;53:388-96. [PMID: 19738485 DOI: 10.1097/QAI.0b013e3181b67527] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
468 Núñez MJ, Martín-carbonero L, Moreno V, Valencia E, Garcia-samaniego J, Castillo JGD, Barreiro P, González-lahoz J, Soriano V. Impact of Antiretroviral Treatment-Related Toxicities on Hospital Admissions in HIV-Infected Patients. AIDS Research and Human Retroviruses 2006;22:825-9. [DOI: 10.1089/aid.2006.22.825] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
469 Merriman RB. Nonalcoholic fatty liver disease and HIV infection. Curr HIV/AIDS Rep 2006;3:113-7. [PMID: 16970837 DOI: 10.1007/BF02696654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
470 Farías AA, Kremer LE, Allende L, Díaz Mdel P, Pisano MB, Contigiani MS, Ré VE. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection. Trans R Soc Trop Med Hyg 2013;107:432-7. [PMID: 23761392 DOI: 10.1093/trstmh/trt043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
471 Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci 2011;56:3038-44. [PMID: 21526398 DOI: 10.1007/s10620-011-1710-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
472 Moreno A, Barcena R, Garcia-garzon S, Moreno L, Quereda C, Muriel A, Zamora J, Mateos ML, Perez-elias MJ, Antela A, Diz S, Moreno A, Moreno S. Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus*. J Viral Hepat 2006;13:466-73. [DOI: 10.1111/j.1365-2893.2005.00710.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
473 Ballesteros ÁL, Franco S, Fuster D, Planas R, Martínez MÁ, Acosta L, Sirera G, Salas A, Tor J, Rey-joly C, Clotet B, Tural C. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004;18:59-66. [DOI: 10.1097/00002030-200401020-00007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
474 Zoller H, Vogel W. Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha. Int J Nanomedicine 2006;1:399-409. [PMID: 17722274 DOI: 10.2147/nano.2006.1.4.399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
475 Bower WA, Culver DH, Castor D, Wu Y, James VN, Zheng H, Hammer S, Kuhnert WL, Williams IT, Bell BP, Vlahov D, Dezzutti CS. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006;42:293-7. [PMID: 16763522 DOI: 10.1097/01.qai.0000221689.77220.42] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
476 Blackard JT, Komurian-Pradel F, Perret M, Sodoyer M, Smeaton L, St Clair JB, Chapman S, Taylor LE, Paranhos-Baccalà G, Chung RT. Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. J Med Virol 2006;78:202-7. [PMID: 16372286 DOI: 10.1002/jmv.20528] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
477 Quereda C, Moreno S, Moreno L, Moreno A, Garcı́a-sanmiguel L, Pérez-elı́as MJ, Navas E, Dronda F, Moreno A, Casado J, Antela A, López-san Román A. The role of liver biopsy in the management of chronic hepatitis C in patients infected with the human immunodeficiency virus. Human Pathology 2004;35:1083-7. [DOI: 10.1016/j.humpath.2004.05.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
478 Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, Tsui JI. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction. 2014;109:62-70. [PMID: 24112091 DOI: 10.1111/add.12367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
479 Moreno A, Bárcena R, García-Garzón S, Muriel A, Quereda C, Moreno L, Mateos ML, Fortún J, Martín-Dávila P, García M, Blesa C, Otón E, Moreno A, Moreno S. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin. J Hepatol 2005;43:783-90. [PMID: 16084622 DOI: 10.1016/j.jhep.2005.05.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
480 N????ez M, Soriano V. Hepatotoxicity of Antiretrovirals: Incidence, Mechanisms and Management. Drug Safety 2005;28:53-66. [DOI: 10.2165/00002018-200528010-00004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
481 Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clinics in Liver Disease 2003;7:475-99. [DOI: 10.1016/s1089-3261(03)00023-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
482 Canchis PW, Yee HT, Fiel MI, Dieterich DT, Liu R, Chiriboga L, Jacobson IM, Edlin BR, Talal AH. Intrahepatic CD4+ Cell Depletion in Hepatitis C Virus/HIV???Coinfected Patients: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2004;37:1125-31. [DOI: 10.1097/01.qai.0000131937.52106.92] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
483 Ray Saraswati L, Sarna A, Sebastian MP, Sharma V, Madan I, Thior I, Pulerwitz J, Tun W. HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India. BMC Public Health 2015;15:726. [PMID: 26223866 DOI: 10.1186/s12889-015-2003-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
484 Qurishi N, Sauerbruch T, Rockstroh J, Spengler U. Effect of HAART on liver-related mortality in patients with HIV/HCV coinfection. The Lancet 2004;363:571. [DOI: 10.1016/s0140-6736(04)15556-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
485 Morgello S, Estanislao L, Ryan E, Gerits P, Simpson D, Verma S, DiRocco A, Sharp V;  Manhattan HIV Brain Bank. Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. AIDS. 2005;19 Suppl 3:S116-S122. [PMID: 16251806 DOI: 10.1097/01.aids.0000192079.49185.f9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
486 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
487 Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected patient. Clin Liver Dis 2003;7:179-94. [PMID: 12691466 DOI: 10.1016/s1089-3261(02)00074-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
488 Sagnelli C, Uberti-Foppa C, Galli L, Pasquale G, Coppola N, Albarello L, Doglioni C, Lazzarin A, Sagnelli E. Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients. Braz J Infect Dis. 2014;18:164-169. [PMID: 24650995 DOI: 10.1016/j.bjid.2013.06.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
489 Wu X, Ishaq M, Hu J, Guo D. HCV NS3/4A protein activates HIV-1 transcription from its long terminal repeat. Virus Res 2008;135:155-60. [PMID: 18433908 DOI: 10.1016/j.virusres.2008.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
490 Shen T, Chen X, Zhang W, Xi Y, Cao G, Zhi Y, Wang S, Xu C, Wei L, Lu F, Zhuang H. A higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patients. PLoS One 2011;6:e23550. [PMID: 21858166 DOI: 10.1371/journal.pone.0023550] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
491 Brennan C. Treatment of hepatitis C virus in the coinfected patient. J Assoc Nurses AIDS Care 2003;14:52S-79S. [PMID: 14571561 DOI: 10.1177/1055329003255837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
492 Fourie J, Flamm J, Rodriguez-french A, Kilby D, Domingo P, Lazzarin A, Ballesteros J, Sosa N, Van De Casteele T, Demasi R, Spinosa-guzman S, Lavreys L. Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96. HIV Clinical Trials 2015;12:313-22. [DOI: 10.1310/hct1206-313] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
493 Resino S, Micheloud D, Miralles P, Bellã³n J, Vargas A, Catalã¡n P, Álvarez E, Cosã­n J, Lorente R, Lã³pez J, Muã±oz-fernã¡ndez M, Berenguer J. Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: the HGM-3 index: Diagnosis of advanced fibrosis. HIV Medicine 2010;11:64-73. [DOI: 10.1111/j.1468-1293.2009.00745.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
494 Berenguer J, Bellón JM, Miralles P, Alvarez E, Sánchez-Conde M, Cosín J, López JC, Alvarez F, Catalán P, Resino S. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007;14:859-69. [PMID: 18070289 DOI: 10.1111/j.1365-2893.2007.00881.x] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
495 Guaraldi G, Cocchi S, Motta A, Ciaffi S, Codeluppi M, Bonora S, Di Benedetto F, Masetti M, Floridia M, Baroncelli S, Pinetti D, D'Avolio A, Bertolini A, Esposito R. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. J Antimicrob Chemother 2008;62:1356-64. [PMID: 18776190 DOI: 10.1093/jac/dkn383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
496 Gluud LL, Marchesini E, Iorio A. Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. Am J Gastroenterol 2009;104:2335-41; quiz 2342. [PMID: 19513022 DOI: 10.1038/ajg.2009.311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
497 Taylor LE, Costello T, Alt E, Yates G, Tashima K. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS 2002;16:1700-1. [PMID: 12172100 DOI: 10.1097/00002030-200208160-00024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
498 Costa MG, Pompei L, Chiarandini P, Lugano M, Baccarani U, Tavio M, Della Rocca G. Perioperative considerations in HIV-infected liver transplanted patients. Transplant Proc 2009;41:1249-52. [PMID: 19460530 DOI: 10.1016/j.transproceed.2009.03.002] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
499 Blackard JT, Sherman KE. HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008;15:323-30. [PMID: 18208497 DOI: 10.1111/j.1365-2893.2008.00970.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
500 Cesari M, Schiavini M, Marchetti G, Caramma I, Ortu M, Franzetti F, Galli M, Antinori S, Milazzo L. Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature. AIDS Patient Care STDS. 2010;24:697-703. [PMID: 20969464 DOI: 10.1089/apc.2010.0160] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
501 Jang JY, Shao RX, Lin W, Weinberg E, Chung WJ, Tsai WL, Zhao H, Goto K, Zhang L, Mendez-Navarro J, Jilg N, Peng LF, Brockman MA, Chung RT. HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol. 2011;54:612-620. [PMID: 21146890 DOI: 10.1016/j.jhep.2010.07.042] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
502 Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. Am J Clin Nutr 2013;98:423-9. [PMID: 23739141 DOI: 10.3945/ajcn.112.048785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
503 Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, Thomas DL, Sulkowski MS. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20:2361-2369. [PMID: 17117023 DOI: 10.1097/qad.0b013e32801086da] [Cited by in Crossref: 100] [Cited by in F6Publishing: 63] [Article Influence: 6.7] [Reference Citation Analysis]
504 Forrester JE, Rhee MS, McGovern BH, Sterling RK, Knox TA, Terrin N. The association of HIV viral load with indirect markers of liver injury. J Viral Hepat. 2012;19:e202-e211. [PMID: 22239520 DOI: 10.1111/j.1365-2893.2011.01529.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
505 Barrett L, Gallant M, Howley C, Ian Bowmer M, Hirsch G, Peltekian K, Grant M. Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection. J Viral Hepat 2011;18:170-80. [PMID: 20497309 DOI: 10.1111/j.1365-2893.2010.01293.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
506 Kong L, Cardona Maya W, Moreno-Fernandez ME, Ma G, Shata MT, Sherman KE, Chougnet C, Blackard JT. Low-level HIV infection of hepatocytes. Virol J 2012;9:157. [PMID: 22877244 DOI: 10.1186/1743-422X-9-157] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
507 Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005;19:585-92. [DOI: 10.1097/01.aids.0000163935.99401.25] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 7.8] [Reference Citation Analysis]
508 Puoti M, Zanini B, Bruno R, Airoldi M, Rossi S, Quiros Roldan E, El Hamad I, Moretti F, Castelli F, Sacchi P, Filice G, Carosi G. Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV. HIV Clin Trials 2002;3:324-32. [PMID: 12187507 DOI: 10.1310/TQFQ-VA2X-95AT-H5LM] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
509 Sterling R. Role of Liver Biopsy in the Evaluation of Hepatitis C Virus Infection in HIV Coinfection. CLIN INFECT DIS 2005;40:S270-5. [DOI: 10.1086/427439] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
510 Ingiliz P, Valantin M, Preziosi P, Finzi L, Pais R, Fedchuk L, Dominguez S, Katlama C, Poynard T, Benhamou Y. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: A retrospective repeated liver biopsy analysis. Journal of Hepatology 2012;56:49-54. [DOI: 10.1016/j.jhep.2011.05.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
511 Sherman KE, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT; AIDS Clinical Trials Group A5178 Study Team. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr 2010;55:597-605. [PMID: 20921898 DOI: 10.1097/QAI.0b013e3181f6d916] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
512 Arnold DM, Julian JA, Walker IR; Association of Hemophilia Clinic Directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006;108:460-4. [PMID: 16551974 DOI: 10.1182/blood-2005-11-4407] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
513 Buti M, Wong J, Casado MA, Esteban R. Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. J Hepatol. 2006;44:S60-S64. [PMID: 16360235 DOI: 10.1016/j.jhep.2005.11.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
514 Aronsohn A, Reau N. Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. Journal of Clinical Gastroenterology 2009;43:661-71. [DOI: 10.1097/mcg.0b013e31819f66e2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
515 Gonzalez VD, Landay AL, Sandberg JK. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol. 2010;135:12-25. [PMID: 20100670 DOI: 10.1016/j.clim.2009.12.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
516 Sekar V, Spinosa-guzman S, De Paepe E, Stevens T, Tomaka F, De Pauw M, Hoetelmans RM. Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment: . Clinical Pharmacokinetics 2010;49:343-50. [DOI: 10.2165/11530690-000000000-00000] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
517 Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, Viard JP, Piketty C, Rouveix E, Rouzioux C. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS. 2006;20:233-240. [PMID: 16511416 DOI: 10.1097/01.aids.0000200541.40633.56] [Cited by in Crossref: 94] [Cited by in F6Publishing: 94] [Article Influence: 5.9] [Reference Citation Analysis]
518 Barreiro P, Martin-carbonero L, Nunez M, Rivas P, Morente A, Simarro N, Labarga P, Gonzalez-lahoz J, Soriano V. Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3. Clinical Infectious Diseases 2006;42:1032-9. [DOI: 10.1086/501021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
519 Soriano V, Martin-carbonero L, Maida I, Garcia-samaniego J, Nuñez M. New paradigms in the management of HIV and hepatitis C virus coinfection: . Current Opinion in Infectious Diseases 2005;18:550-60. [DOI: 10.1097/01.qco.0000191509.56104.ec] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
520 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
521 Klenerman P, Kim A. HCV-HIV coinfection: simple messages from a complex disease. PLoS Med 2007;4:e240. [PMID: 17927445 DOI: 10.1371/journal.pmed.0040240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
522 Lieveld FI, Smit C, Richter C, van Erpecum KJ, Spanier BWM, Gisolf EH, Vrolijk JM, Siersema PD, Hoepelman AIM, Reiss P, Arends JE. Liver decompensation in HIV/Hepatitis B coinfection in the combination antiretroviral therapy era does not seem increased compared to hepatitis B mono-infection. Liver Int 2019;39:470-83. [PMID: 30411848 DOI: 10.1111/liv.14000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
523 Smith DK, Gardner LI, Phelps R, Hamburger ME, Carpenter C, Klein RS, Rompalo A, Schuman P, Holmberg SD; HIV Epidemiology Rsearch Study Group. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health 2003;80:676-88. [PMID: 14709715 DOI: 10.1093/jurban/jtg074] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
524 Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology. 2011;140:809-817. [PMID: 21134375 DOI: 10.1053/j.gastro.2010.11.052] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
525 Sherman KE, Rouster SD, Stanford S, Blackard JT, Shire N, Koziel M, Peters M, Chung RT; AIDS Clinical Trials Group 5071 Study Team. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis 2010;201:712-9. [PMID: 20105080 DOI: 10.1086/650490] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
526 Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One. 2009;4:e4517. [PMID: 19223976 DOI: 10.1371/journal.pone.0004517] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
527 Shire NJ, Rouster SD, Stanford SD, Blackard JT, Martin CM, Fichtenbaum CJ, Sherman KE. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44:309-314. [PMID: 17159656 DOI: 10.1097/qai.0b013e31802e29a9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
528 Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation. 2008;85:359-368. [PMID: 18301332 DOI: 10.1097/tp.0b013e3181605fda] [Cited by in Crossref: 47] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
529 Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008;103:905-18. [PMID: 18422827 DOI: 10.1111/j.1360-0443.2008.02188.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
530 Ribes J, Cl??ries R, Borr??s J, Galceran J, Bosch FX. Time trends in incidence and mortality for chronic liver disease and liver cancer in the interval 1980???1997 in Catalonia, Spain: . European Journal of Gastroenterology & Hepatology 2004;16:865-72. [DOI: 10.1097/00042737-200409000-00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
531 Laguno M, Sánchez-tapias JM, Murillas J, Forns X, Blanco JL, Martínez E, Larrousse M, León A, Loncá M, Milinkovic A, Miró JM, García F, Gatell JM, Mallolas J. Avances en el diagnóstico y tratamiento de la infección por el VHC en pacientes con y sin infección por el VIH. Enfermedades Infecciosas y Microbiología Clínica 2005;23:32-40. [DOI: 10.1157/13070408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
532 Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36:97-100. [PMID: 12491208 DOI: 10.1086/344907] [Cited by in Crossref: 121] [Cited by in F6Publishing: 126] [Article Influence: 6.1] [Reference Citation Analysis]
533 Achhra AC, Zhou J, Choi JY, Hoy J, Zhang F, Templeton DJ, Merati T, Woolley I, Petoumenos K, Amin J; TAHOD and AHOD. The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD. J Int Assoc Physicians AIDS Care (Chic) 2011;10:160-70. [PMID: 21508296 DOI: 10.1177/1545109711402213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
534 Palepu A, Cheng DM, Kim T, Nunes D, Vidaver J, Alperen J, Saitz R, Samet JH. Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems. J Subst Abuse Treat 2006;31:411-7. [PMID: 17084795 DOI: 10.1016/j.jsat.2006.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
535 Moreno S, García-Samaniego J, Moreno A, Ortega E, Pineda JA, del Romero J, Tural C, von Wichmann MA, Berenguer J, Castro A. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat. 2009;16:249-258. [PMID: 19215579 DOI: 10.1111/j.1365-2893.2009.01088.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
536 Campa A, Martinez SS, Sherman KE, Greer JP, Li Y, Garcia S, Stewart T, Ibrahimou B, Williams OD, Baum MK. Cocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort. J Drug Abuse 2016;2:27. [PMID: 28540368 DOI: 10.21767/2471-853X.100036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
537 Núñez M, Soriano V. How effective is HAART in HCV and HIV coinfection?: . AIDS 2004;18:2081-4. [DOI: 10.1097/00002030-200410210-00013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
538 Vyas JJ, Brown RS, Gaglio PJ. Hepatitis C-HIV coinfection: current and future therapy. Expert Rev Anti Infect Ther 2003;1:433-9. [PMID: 15482140 DOI: 10.1586/14787210.1.3.433] [Reference Citation Analysis]
539 Mcgovern B, Bica I, Snydman DR, Mcgowan K, Stone D. Reply. CLIN INFECT DIS 2001;33:1796-7. [DOI: 10.1086/323012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
540 de la Mata M, Barrera P, Fraga E, Montero JL, de la Torre J, López-Cillero P, Briceño J, Solórzano G, Alonso M. [Liver transplantation in patients with HIV infection]. Gastroenterol Hepatol 2004;27:425-8. [PMID: 15461943 DOI: 10.1016/s0210-5705(03)70492-0] [Reference Citation Analysis]
541 Mendes-Corrêa M, Núñez M. Management of HIV and hepatitis virus coinfection. Expert Opin Pharmacother 2010;11:2497-516. [PMID: 20629586 DOI: 10.1517/14656566.2010.500615] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
542 Vento S, Cainelli F. Does hepatitis C virus cause severe liver disease only in people who drink alcohol? The Lancet Infectious Diseases 2002;2:303-9. [DOI: 10.1016/s1473-3099(02)00271-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
543 Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [PMID: 19330875 DOI: 10.1002/hep.22759] [Cited by in Crossref: 2134] [Cited by in F6Publishing: 1938] [Article Influence: 164.2] [Reference Citation Analysis]
544 Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel: . AIDS 2002;16:813-28. [DOI: 10.1097/00002030-200204120-00001] [Cited by in Crossref: 187] [Cited by in F6Publishing: 163] [Article Influence: 9.4] [Reference Citation Analysis]
545 Wagner G, Osilla KC, Garnett J, Ghosh-Dastidar B, Bhatti L, Witt M, Goetz MB. Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients. J Int Assoc Physicians AIDS Care (Chic) 2012;11:245-51. [PMID: 22564797 DOI: 10.1177/1545109712444163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
546 Fung J, Eghtesad B, Patel-tom K, Devera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl 2004;10:S39-53. [DOI: 10.1002/lt.20261] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
547 Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity – a challenge for the hepatologist? Journal of Hepatology 2002;36:283-94. [DOI: 10.1016/s0168-8278(01)00311-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
548 Rockstroh JK, Soriano V, Plonski F, Bansal M, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Mukwaya G, Jagannatha S, Heera J, Pineda JA. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. HIV Clinical Trials 2015;16:72-80. [DOI: 10.1179/1528433614z.0000000011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
549 Saha B, Choudhary MC, Sarin SK. Expression of inhibitory markers is increased on effector memory T cells during hepatitis C virus/HIV coinfection as compared to hepatitis C virus or HIV monoinfection. AIDS 2013;27:2191-200. [PMID: 23820090 DOI: 10.1097/QAD.0b013e32836285e4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
550 Olagbenro M, Anderson M, Gaseitsiwe S, Powell EA, Gededzha MP, Selabe SG, Blackard JT. In silico analysis of mutations associated with occult hepatitis B virus (HBV) infection in South Africa. Arch Virol 2021;166:3075-84. [PMID: 34468889 DOI: 10.1007/s00705-021-05196-7] [Reference Citation Analysis]
551 Feeney E, Muldoon E, Powderly WG. Management of antiretroviral drug toxicity. Curr Opin HIV AIDS 2006;1:430-6. [PMID: 19372843 DOI: 10.1097/01.COH.0000239856.45485.db] [Reference Citation Analysis]
552 Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-samaniego J, Soriano V. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 2007;14:387-91. [DOI: 10.1111/j.1365-2893.2006.00806.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
553 Pol S, Soriano V. Management of Chronic Hepatitis C Virus Infection in HIV‐Infected Patients. CLIN INFECT DIS 2008;47:94-101. [DOI: 10.1086/588669] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
554 Martín-carbonero L, Sánchez-somolinos M, García-samaniego J, Núñez MJ, Valencia ME, González-lahoz J, Soriano V. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. J Viral Hepat 2006;13:851-7. [DOI: 10.1111/j.1365-2893.2006.00778.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
555 McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, McGrath D, Farajallah A, Moyle G. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012;26:259-64. [PMID: 22404426 DOI: 10.1089/apc.2011.0092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
556 Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039-2045. [PMID: 15577625 DOI: 10.1097/00002030-200410210-00008] [Cited by in Crossref: 188] [Cited by in F6Publishing: 169] [Article Influence: 11.1] [Reference Citation Analysis]
557 Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 2012;55:507-13. [PMID: 22523269 DOI: 10.1093/cid/cis432] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
558 Sollima S, Caramma I, Menzaghi B, Massetto B, Acquaviva V, Giulani G, Moroni M, Antinori S. Chronic coinfection with hepatitis B and hepatitis C viruses in an Italian population of HIV-infected patients. J Acquir Immune Defic Syndr 2007;44:606-7. [PMID: 17413991 DOI: 10.1097/QAI.0b013e318031d5b5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
559 Birkhead GS, Klein SJ, Candelas AR, O’connell DA, Rothman JR, Feldman IS, Tsui DS, Cotroneo RA, Flanigan CA. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: A comprehensive approach. International Journal of Drug Policy 2007;18:417-25. [DOI: 10.1016/j.drugpo.2007.01.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
560 Kramer JR, Giordano TP, El-Serag HB. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol 2007;5:1321-1328.e7. [PMID: 17981246 DOI: 10.1016/j.cgh.2007.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
561 Ganesan M, Poluektova LY, Kharbanda KK, Osna NA. Liver as a target of human immunodeficiency virus infection. World J Gastroenterol 2018; 24(42): 4728-4737 [PMID: 30479460 DOI: 10.3748/wjg.v24.i42.4728] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
562 Antonello VS, Tovo CV, Kliemann DA, Santos BR, Zaltron VF. [Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients]. Rev Soc Bras Med Trop 2010;43:678-81. [PMID: 21181022 DOI: 10.1590/s0037-86822010000600015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
563 Rockstroh JK. Should HIV/HCV coinfected patients with severe hepatitis be treated for hepatitis C. Presse Med 2005;34:1585-8. [PMID: 16314818 DOI: 10.1016/s0755-4982(05)84229-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
564 Rodríguez-torres M, Rodríguez-orengo JF, Ríos-bedoya CF, Fernández-carbia A, Marxuach-cuétara AM, López-torres A, Jiménez-rivera J. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: A paired liver biopsy study. Journal of Hepatology 2007;46:613-9. [DOI: 10.1016/j.jhep.2006.12.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
565 Butt AA, Khan UA, Skanderson M. Comorbidities and Their Impact on Mortality in HCV and HCV-HIV–coinfected Persons on Dialysis. Journal of Clinical Gastroenterology 2008;42:1054-9. [DOI: 10.1097/mcg.0b013e3181574d58] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
566 Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007;21:1301-8. [PMID: 17545706 DOI: 10.1097/QAD.0b013e32814e6b08] [Cited by in Crossref: 104] [Cited by in F6Publishing: 69] [Article Influence: 6.9] [Reference Citation Analysis]
567 Núñez M, Soriano V. New Hopes for HIV and HCV Coinfection in 2004. HIV Clinical Trials 2015;5:232-51. [DOI: 10.1310/geuc-ngkm-xugu-4x94] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
568 Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, Volberding PA. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis 2007;44:1375-83. [PMID: 17443478 DOI: 10.1086/515398] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
569 Rosen MJ, Narasimhan M. Critical care of immunocompromised patients: human immunodeficiency virus. Crit Care Med 2006;34:S245-50. [PMID: 16917430 DOI: 10.1097/01.CCM.0000232491.15369.AB] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
570 Dove LM. A general approach to the management of chronic hepatitis C. Gastroenterology Clinics of North America 2004;33:463-77. [DOI: 10.1016/j.gtc.2004.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
571 Baccarani U, Righi E, Adani GL, Lorenzin D, Pasqualucci A, Bassetti M, Risaliti A. Pros and cons of liver transplantation in human immunodeficiency virus infected recipients. World J Gastroenterol 2014; 20(18): 5353-5362 [PMID: 24833865 DOI: 10.3748/wjg.v20.i18.5353] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
572 McGovern BH. Editorial commentary: Hepatitis C virus and the infectious disease physician: a perfect match. Clin Infect Dis 2012;55:414-7. [PMID: 22491341 DOI: 10.1093/cid/cis378] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
573 Maida I, Soriano V, Ramos B, Ríos P, González-lahoz J, Núñez M. Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfected Population Followed at a Reference HIV Center. HIV Clinical Trials 2015;6:329-36. [DOI: 10.1310/25kl-0vtl-jwxp-fe6y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.9] [Reference Citation Analysis]
574 Fuster D, Sanvisens A, Bolao F, Rivas I, Tor J, Muga R. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol 2016; 8(31): 1295-1308 [PMID: 27872681 DOI: 10.4254/wjh.v8.i31.1295] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
575 Bonacini M. Diagnosis and Management of Cirrhosis in Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;45:S38-46. [DOI: 10.1097/qai.0b013e318068d151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
576 Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J, Sirera G, Guardiola H, Salas A, Cabré E, Ojanguren I, Barluenga E, Rey-joly C, Clotet B, Tural C. Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients on Antiretroviral Therapy. AIDS Research and Human Retroviruses 2004;20:1293-7. [DOI: 10.1089/aid.2004.20.1293] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
577 Clanon KA, Johannes Mueller J, Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 2005;40 Suppl 5:S362-6. [PMID: 15768349 DOI: 10.1086/427454] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
578 Sherman AC, Trehanpati N, Daucher M, Davey RT, Masur H, Sarin SK, Kottilil S, Kohli A. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir. AIDS Res Hum Retroviruses. 2013;29:665-672. [PMID: 23259453 DOI: 10.1089/AID.2012.0320] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
579 Sulkowski MS. Therapy Insight: management of hepatitis C in patients coinfected with HIV. Nat Rev Gastroenterol Hepatol 2005;2:223-31. [DOI: 10.1038/ncpgasthep0170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
580 Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat 2006;13:678-82. [PMID: 16970599 DOI: 10.1111/j.1365-2893.2006.00740.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
581 Hoefs J, Aulakh VS. Treatment of chronic HCV infection in special populations. Int J Med Sci 2006;3:69-74. [PMID: 16614746 DOI: 10.7150/ijms.3.69] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
582 Weiss JJ, Gorman JM. Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep 2006;3:176-81. [PMID: 17032577 DOI: 10.1007/s11904-006-0013-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
583 Revill PA, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A, Sasaduesz J, Lewin SR, Dore GJ, Matthews GV, Thio CL, Locarnini SA. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS. 2007;21:1701-1710. [PMID: 17690567 DOI: 10.1097/qad.0b013e32826fb305] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
584 Hirose K, Stock PG. Liver transplantation in the human immunodeficiency virus-positive patient: . Current Opinion in Organ Transplantation 2006;11:241-6. [DOI: 10.1097/01.mot.0000227839.83710.e5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
585 Akhtar MA, Mathieson K, Arey B, Post J, Prevette R, Hillier A, Patel P, Ram LJ, Van Thiel DH, Nadir A. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis: . European Journal of Gastroenterology & Hepatology 2008;20:1194-204. [DOI: 10.1097/meg.0b013e328305b9e0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
586 Powderly WG. Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. Clin Infect Dis. 2004;38 Suppl 2:S109-S113. [PMID: 14986283 DOI: 10.1086/381443] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
587 Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P; Manhattan HIV Brain Bank. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004;62:957-62. [PMID: 15037699 DOI: 10.1212/01.wnl.0000115177.74976.6c] [Cited by in Crossref: 113] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
588 Taylor LE, Bowman SE, Chapman S, Zaller N, Stein MD, Cioe PA, Maynard MA, McGovern BH. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug Alcohol Depend 2011;116:233-7. [PMID: 21177046 DOI: 10.1016/j.drugalcdep.2010.11.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
589 Pau AK, Mclaughlin MM, Hu Z, Agyemang AF, Polis MA, Kottilil S. Predictors for Hematopoietic Growth Factors Use in HIV/HCV-Coinfected Patients Treated with Peginterferon Alfa 2b and Ribavirin. AIDS Patient Care and STDs 2006;20:612-9. [DOI: 10.1089/apc.2006.20.612] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
590 Adeyemi OM, Jensen D, Attar B, Ghaoui R, Gallagher M, Wolen D, Cotler SJ. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS. 2004;18:239-245. [PMID: 15142354 DOI: 10.1089/108729104323038919] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
591 Jou JH, Muir AJ. In the clinic. Hepatitis C. Ann Intern Med 2008;148:ITC6-1-ITC6-16. [PMID: 18519925 DOI: 10.7326/0003-4819-148-11-200806030-01006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
592 Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Agüero F, Abradelo M, Miralles P, Torre-Cisneros J, Pedreira JD. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12:1866-1876. [PMID: 22471341 DOI: 10.1111/j.1600-6143.2012.04028.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 10.9] [Reference Citation Analysis]
593 Sulkowski MS, Felizarta F, Smith C, Slim J, Berggren R, Goodman R, Ball L, Khalili M, Dieterich DT; Hepatitis Resource Network Clinical Trials Group. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004;35:464-72. [PMID: 15021311 DOI: 10.1097/00126334-200404150-00004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
594 Al-Harthi L, Voris J, Du W, Wright D, Nowicki M, Frederick T, Landay A, Kovacs A. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis 2006;193:1202-10. [PMID: 16586355 DOI: 10.1086/500843] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
595 Heuft MM, Houba SM, van den Berk GE, Smissaert van de Haere T, van Dam AP, Dijksman LM, Regez RM, Brinkman K. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS 2014;28:999-1005. [DOI: 10.1097/qad.0000000000000180] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
596 McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007;45 Suppl 2:S47-56; discussion S66-7. [PMID: 17704692 DOI: 10.1097/QAI.0b013e318068d190] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
597 Klein MB, Rollet-Kurhajec KC, Moodie EE, Yaphe S, Tyndall M, Walmsley S, Gill J, Martel-Laferriere V, Cooper C. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). AIDS. 2014;28:1957-1965. [PMID: 25259703 DOI: 10.1097/qad.0000000000000377] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
598 Jafferbhoy H, Gashau W, Dillon J. Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon Outcomes Res 2010;2:87-96. [PMID: 21935317 DOI: 10.2147/ceor.s7283] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
599 Dodig M, Tavill AS. Hepatitis C and human immunodeficiency virus coinfections. J Clin Gastroenterol. 2001;33:367-374. [PMID: 11606851 DOI: 10.1097/00004836-200111000-00005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
600 Gardner LI, Klein RS, Szczech LA, Phelps RM, Tashima K, Rompalo AM, Schuman P, Sadek RF, Tong TC, Greenberg A, Holmberg SD. Rates and Risk Factors for Condition-Specific Hospitalizations in HIV-Infected and Uninfected Women: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;34:320-30. [DOI: 10.1097/00126334-200311010-00011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
601 Klein SJ, Flanigan CA, Cooper JG, Holtgrave DR, Carrascal AF, Birkhead GS. Wanted: An Effective Public Health Response to Hepatitis C Virus in the United States. Journal of Public Health Management and Practice 2008;14:471-5. [DOI: 10.1097/01.phh.0000333882.52893.81] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
602 Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, Lüth S, van Lunzen J, Schulze Zur Wiesch J. German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients. AIDS Res Ther 2014;11:16. [PMID: 25006340 DOI: 10.1186/1742-6405-11-16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
603 Dehghan Manshadi SA, Merat S, Mohraz M, Rasoolinejad M, Sali S, Mardani M, Tabarsi P, Somi MH, Sedghi R, Tayeri K, Nikbin M, Karimi J, Sharifi AH, Kalantari S, Norouzi A, Merat D, Malekzadeh Z, Mirminachi B, Poustchi H, Malekzadeh R. Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus. Int J Clin Pract 2021;75:e14304. [PMID: 33930223 DOI: 10.1111/ijcp.14304] [Reference Citation Analysis]
604 Martín-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcorreta A, Gonzalez A, Rockstroh J, Asensi V. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38:128-133. [PMID: 14679458 DOI: 10.1086/380130] [Cited by in Crossref: 198] [Cited by in F6Publishing: 182] [Article Influence: 10.4] [Reference Citation Analysis]
605 Pozza R, Barakat F, Barber E. Adherence to therapy: Challenges in HCV-infected patients. Curr hepatitis rep 2007;6:160-8. [DOI: 10.1007/s11901-007-0019-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
606 Basseri B, Yamini D, Chee G, Enayati PDP, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection: Hepatitis C and comorbidities. Liver International 2010;30:1012-8. [DOI: 10.1111/j.1478-3231.2010.02235.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
607 Smith JO, Sterling RK. HIV coinfection with hepatitis C and hepatitis B. Curr Infect Dis Rep 2006;8:409-18. [PMID: 16934201 DOI: 10.1007/s11908-006-0053-1] [Reference Citation Analysis]
608 Lo Re V 3rd, Kostman JR, Amorosa VK. Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 2008;12:587-609, ix. [PMID: 18625430 DOI: 10.1016/j.cld.2008.03.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
609 Ghare SS, Donde H, Chen WY, Barker DF, Gobejishvilli L, McClain CJ, Barve SS, Joshi-Barve S. Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine. Toxicol In Vitro 2016;35:66-76. [PMID: 27238871 DOI: 10.1016/j.tiv.2016.05.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
610 Butt AA, Tsevat J, Ahmad J, Shakil AO, Mrus JM. Biochemical and virologic parameters in patients co-infected with hepatitis C and HIV versus patients with hepatitis C mono-infection. Am J Med Sci. 2007;333:271-275. [PMID: 17505167 DOI: 10.1097/maj.0b013e31805341f0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
611 Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiol Drug Saf. 2009;18:848-857. [PMID: 19551698 DOI: 10.1002/pds.1793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
612 Leeming DJ, Anadol E, Schierwagen R, Karsdal MA, Byrjalsen I, Nielsen MJ, Schwarzer-zander C, Boesecke C, Bendtsen F, Møller S, Strassburg CP, Spengler U, Krag A, Rockstroh J, Trebicka JK. Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. AIDS 2014;28:2081-90. [DOI: 10.1097/qad.0000000000000388] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
613 Chu F, Chiang S, Su F, Chang Y, Cheng S. Prevalence of human immunodeficiency virus and its association with hepatitis B, C, and D virus infections among incarcerated male substance abusers in Taiwan. J Med Virol 2009;81:973-8. [DOI: 10.1002/jmv.21481] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
614 Attia KA. Co-infection VIH-VHB au sud du Sahara : données épidémiologiques, cliniques et thérapeutiques. J Afr Hepato Gastroenterol 2007;1:51-3. [DOI: 10.1007/s12157-007-0011-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
615 Claret-Teruel G, Noguera-Julian A, Esteva C, Muñoz-Almagro C, Sánchez E, Jiménez R, Fortuny C. Impact of human immunodeficiency virus coinfection on the progression of mother-to-child transmitted hepatitis C virus infection. Pediatr Infect Dis J 2011;30:801-4. [PMID: 21772231 DOI: 10.1097/INF.0b013e3182196ab4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
616 Micheloud D, González-nicolás J, Berenguer J, Lorente R, Miralles P, López J, Cosín J, Catalán P, Muñoz-fernández M, Resino S. CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients. HIV Medicine 2010;11:161-9. [DOI: 10.1111/j.1468-1293.2009.00758.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
617 Taege A. Organ Transplantation and HIV Progress or Success? A Review of Current Status. Curr Infect Dis Rep 2013;15:67-76. [PMID: 23242762 DOI: 10.1007/s11908-012-0309-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
618 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
619 Frühauf NR, Köditz R, Radecke K, Malagó M, Lang H, Broelsch CE. [Organ transplantation in human immunodeficiency virus-infected patients. Results of a survey in German transplantation centres]. Chirurg 2004;75:681-6. [PMID: 15258750 DOI: 10.1007/s00104-004-0825-9] [Reference Citation Analysis]
620 Blackard JT, Ma G, Sengupta S, Martin CM, Powell EA, Shata MT, Sherman KE. Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV. J Med Virol. 2014;86:1332-1341. [PMID: 24788693 DOI: 10.1002/jmv.23968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
621 Peter J, Frey O, Stallmach A, Bruns T. Attenuated antigen-specific T cell responses in cirrhosis are accompanied by elevated serum interleukin-10 levels and down-regulation of HLA-DR on monocytes. BMC Gastroenterol. 2013;13:37. [PMID: 23446058 DOI: 10.1186/1471-230x-13-37] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
622 Real LM, Caruz A, Rivero-juarez A, Soriano V, Neukam K, Rivero A, Cifuentes C, Mira JA, Macías J, Pineda JA. A polymorphism linked to RRAS , SCAF1 , IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers. Liver Int 2014;34:558-66. [DOI: 10.1111/liv.12330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
623 Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 2006;44:1026-1032. [PMID: 16618518 DOI: 10.1016/j.jhep.2006.02.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.0] [Reference Citation Analysis]
624 Gonzalez VD, Falconer K, Blom KG, Reichard O, Mørn B, Laursen AL, Weis N, Alaeus A, Sandberg JK. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol. 2009;83:11407-11411. [PMID: 19710147 DOI: 10.1128/jvi.01211-09] [Cited by in Crossref: 107] [Cited by in F6Publishing: 58] [Article Influence: 8.2] [Reference Citation Analysis]
625 Dillon AA, Farrell G, Hegarty JE, O'Grady JG, Norris S, Bergin C. The advent of successful organ transplantation in the Irish HIV positive cohort. Ir J Med Sci 2012;181:49-52. [PMID: 21853387 DOI: 10.1007/s11845-011-0746-9] [Reference Citation Analysis]
626 Park JS, Saraf N, Dieterich DT. Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV. Curr hepatitis rep 2005;4:68-74. [DOI: 10.1007/s11901-005-0017-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
627 Schwarze-Zander C, Blackard JT, Rockstroh JK. Role of GB virus C in modulating HIV disease. Expert Rev Anti Infect Ther 2012;10:563-72. [PMID: 22702320 DOI: 10.1586/eri.12.37] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
628 . The impact of HIV on mortality rates in the complete UK haemophilia population: . AIDS 2004;18:525-33. [DOI: 10.1097/00002030-200402200-00020] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
629 Sánchez-conde M, Miralles P, María Bellón J, Rincón D, Ramírez M, Gutiérrez I, Ripoll C, López JC, Cosín J, Clemente G, Lo Iacono O, Bañares R, Berenguer J. Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients: Transient elastography and hepatic venous pressure gradient. Journal of Viral Hepatitis 2011;18:685-91. [DOI: 10.1111/j.1365-2893.2010.01371.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
630 Kong L, Welge JA, Powell EA, Blackard JT. HIV infection of hepatocytes results in a modest increase in hepatitis C virus expression in vitro. PLoS One 2014;9:e83728. [PMID: 24586227 DOI: 10.1371/journal.pone.0083728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
631 Smith JO, Sterling RK. Hepatitis C and HIV. Curr Gastroenterol Rep 2007;9:83-90. [PMID: 17335682 DOI: 10.1007/s11894-008-0025-8] [Reference Citation Analysis]
632 Attia KA, Eholié S, Messou E, Danel C, Polneau S, Chenal H, Toni T, Mbamy M, Seyler C, Wakasugi N, N’dri-Yoman T, Anglaret X. Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol 2012; 4(7): 218-223 [PMID: 22855697 DOI: 10.4254/wjh.v4.i7.218] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
633 Schiavini M, Angeli E, Mainini A, Zerbi P, Duca PG, Gubertini G, Vago L, Fociani P, Giorgi R, Cargnel A. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med 2006;7:331-7. [PMID: 16945079 DOI: 10.1111/j.1468-1293.2006.00384.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
634 Conway B, Tossonian H. Comprehensive Approaches to the Diagnosis and Treatment of HIV Infection in the Community: Can "Seek and Treat" Really Deliver? Curr Infect Dis Rep 2011;13:68-74. [PMID: 21308457 DOI: 10.1007/s11908-010-0151-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
635 Saifee S, Joelson D, Braude J, Shrestha R, Johnson M, Sellers M, Galambos MR, Rubin RA. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol. 2008;6:1167-1169. [PMID: 18639498 DOI: 10.1016/j.cgh.2008.04.023] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
636 Neff GW, Shire NJ, Rudich SM. Outcomes among Patients with End-Stage Liver Disease Who Are Coinfected with HIV and Hepatitis C Virus. Clinical Infectious Diseases 2005;41:S50-5. [DOI: 10.1086/429496] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
637 Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, Jabs DA. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis. 2012;55:137-144. [PMID: 22534149 DOI: 10.1093/cid/cis404] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
638 Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. J Acquir Immune Defic Syndr. 2003;34 Suppl 1:S59-S65. [PMID: 14562859 DOI: 10.1097/00126334-200309011-00009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
639 Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006;6:753-760. [PMID: 16539632 DOI: 10.1111/j.1600-6143.2006.01238.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 5.2] [Reference Citation Analysis]
640 Miró JM, Montejo M, Rufí G, Bárcena R, Vargas V, Rimola A, Bañares R, Valdivieso A, Fabregat J, Vicente ED, Margarit C, Moreno A, Miralles P, Aguirrebengoa K, Xiol FX, Fortún J, Pahissa A, Laguno M, Salcedo M, Cisneros JM, Quereda C, Tuset M, Castón JJ, Torre-cisnerosh J. Trasplante hepático en pacientes con infección por el VIH: una realidad en el año 2004. Enfermedades Infecciosas y Microbiología Clínica 2004;22:529-38. [DOI: 10.1016/s0213-005x(04)73155-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
641 Rodriguez-merchan EC. HIV and HCV coinfected haemophilia patients: what are the best options of orthopaedic treatment? Haemophilia 2006;12:90-101. [DOI: 10.1111/j.1365-2516.2006.01264.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
642 Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS 2005;19:S208-14. [DOI: 10.1097/01.aids.0000192091.38883.f9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
643 Ishida Y, Hayashida T, Sugiyama M, Tsuchiya K, Kikuchi Y, Mizokami M, Oka S, Gatanaga H. Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo. J Acquir Immune Defic Syndr 2019;80:350-7. [PMID: 30550489 DOI: 10.1097/QAI.0000000000001919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
644 Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lombès A. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009;49:436-442. [PMID: 19085967 DOI: 10.1002/hep.22665] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 8.2] [Reference Citation Analysis]
645 Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverría S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-burruezo JJ, Guardiola JM, Romero M, García-samaniego J, Soriano V; On Behalf Of The PRESCO Study Group. Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. AIDS Research and Human Retroviruses 2007;23:972-82. [DOI: 10.1089/aid.2007.0011] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 9.5] [Reference Citation Analysis]
646 Araújo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, de Melo ES, Layden TJ, Cotler SJ, Barone AA. Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat 2011;18:e52-60. [PMID: 20738775 DOI: 10.1111/j.1365-2893.2010.01358.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
647 Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl. 2009;15:1133-1141. [PMID: 19718643 DOI: 10.1002/lt.21735] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
648 Campos-Varela I, Dodge JL, Terrault NA, Brandman D, Price JC. Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus. Am J Transplant 2021;21:3148-56. [PMID: 33749113 DOI: 10.1111/ajt.16569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
649 Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, Lloyd AR, Jaworowski A, French MA, Lewin SR. HIV and co-infections. Immunol Rev 2013;254:114-42. [PMID: 23772618 DOI: 10.1111/imr.12063] [Cited by in Crossref: 75] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
650 Wagner G, Ryan G, Osilla KC, Bhatti L, Goetz M, Witt M. Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care STDS 2009;23:715-25. [PMID: 19663714 DOI: 10.1089/apc.2009.0049] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
651 Proeschold-Bell RJ, Hoeppner B, Taylor B, Cohen S, Blouin R, Stringfield B, Muir AJ. An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. AIDS Behav 2011;15:1721-31. [PMID: 21191643 DOI: 10.1007/s10461-010-9870-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
652 Mcgovern B. A Golden Opportunity: The Treatment of Hepatitis C in HIV-Infected Inmates. Journal of Addictive Diseases 2008;27:69-73. [DOI: 10.1300/j069v27n02_08] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
653 Takatsuki M, Soyama A, Eguchi S. Liver transplantation for HIV/hepatitis C virus co-infected patients. Hepatol Res. 2014;44:17-21. [PMID: 23607831 DOI: 10.1111/hepr.12132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
654 Padam P, Clark S, Irving W, Gellissen R, Thomson E, Main J, Cooke GS. Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease. J Viral Hepat 2016;23:123-9. [PMID: 26511293 DOI: 10.1111/jvh.12484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
655 Gonzalez SA, Liu R, Edlin BR, Jacobson IM, Talal AH. HIV/Hepatitis C Virus-Coinfected Patients With Normal Alanine Aminotransferase Levels. JAIDS Journal of Acquired Immune Deficiency Syndromes 2006;41:582-9. [DOI: 10.1097/01.qai.0000214806.90841.c8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
656 Soriano V. Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. J Hepatol 2006;44:S44-8. [PMID: 16352362 DOI: 10.1016/j.jhep.2005.11.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]